Traditional chinese medicine composition having efficacy in treating colds and use thereof

MYPI2025004235A0Undetermined Publication Date: 2024-07-17SHIJIAZHUANG YILING PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004235
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-17
Filing Date
2024-01-24
Publication Date
2024-07-17

AI Technical Summary

Technical Problem

Existing Western medicines for treating colds are not very effective in relieving respiratory and digestive symptoms, and the combined use of multiple drugs increases the risk of adverse reactions for patients. There is a lack of comprehensive treatment options for wind-evil attacking the exterior and dampness obstructing the middle jiao.

Method used

Combining the theory of collaterals in traditional Chinese medicine, this formula uses modified versions of Huoxiang Zhengqi San, Huopu Xialing Tang, and Xinjia Xiangru Yin. It employs pungent and warm aromatic herbs such as perilla leaves and patchouli to disperse and relieve exterior symptoms, resolve dampness and harmonize the middle jiao, and combines them with light and refreshing herbs to soothe the skin surface, regulate qi and dry dampness, and regulate the functions of the spleen, stomach and intestines. The formula is prepared into dosage forms such as capsules, tablets and granules.

Benefits of technology

It significantly relieves symptoms such as fever, nasal congestion, headache, nausea, vomiting, and diarrhea caused by the common cold, regulates the balance of immune cells, reduces local tissue inflammation, improves patient compliance, and provides holistic treatment effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A traditional Chinese medicine composition having efficacy in treating colds and a use thereof. The traditional Chinese medicine composition is prepared from perilla leaf, cabline potchouli, all-grass of haichow elsholtzia, bark of officinal magnolia, root of baikal skullcap, alum-processed pinellia ternata tuber, lonicera confusa, weeping forsythia capsule, Fu Ling, dried tangerine peel, and fresh ginger, and is capable of relieving exterior syndrome and harmonizing the middle, expelling uncleanliness and resolving dampness, and treating symptoms such as cold, fever, aversion to wind, stuffy and runny nose, headache and drowsiness, nausea and vomiting, diarrhea, heaviness in limbs, abdominal swelling and pain, decreased appetite and anorexia.
Need to check novelty before this filing date? Find Prior Art

Description

A Chinese medicine composition with cold-treating effect and its application This application claims the priority of the Chinese patent application filed with the China Patent Office on January 17, 2023, with application number 202310058976.3 and invention name “A Chinese medicine composition with therapeutic effect on colds and its application”, the entire contents of which are incorporated by reference into this application. Technical Field The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition having the effect of treating colds and application thereof. Background Art As the most common acute respiratory infection, colds are characterized by nasal congestion, runny nose, headache, sneezing, fever, chills, cough and other symptoms. They are common causes of diseases such as asthma and pneumonia, and can even cause serious complications such as secondary bacterial infection, asthma exacerbation, and chronic obstructive pulmonary disease. The severity of cold symptoms peaks 2 to 3 days after infection, and generally recovers after 5 to 7 days, but some symptoms can last for more than 3 weeks. It is reported that the number of people who visit the doctor for colds is as high as 2.7 billion each year, with adults getting sick 2 to 6 times per year on average and children 6 to 8 times per year. The annual incidence rate of community residents in my country is as high as 83.27%. According to data from the United States, the high incidence and frequency of colds have led to a high rate of missed work and school. The annual cost of over-the-counter drugs used to relieve cold symptoms is as high as $2 billion, and the cost of antibacterial drugs is as high as $2.27 billion. The treatment of complications and exacerbations of the primary disease has further increased medical expenses, increasing the burden of disease treatment. Although this disease is a common disease, it has a high incidence and frequency, and can easily cause more serious clinical consequences and increase the burden of the disease. Effective therapeutic drugs are urgently needed to improve clinical symptoms. Common viruses that cause colds include rhinovirus, coronavirus, coxsackie virus, parainfluenza virus, respiratory syncytial virus, etc. The virus replicates in the respiratory epithelial cells and local lymphoid tissues, releasing a variety of inflammatory mediators to cause inflammatory reactions, clinically manifesting a series of respiratory symptoms and fever, pain and other systemic symptoms. The symptoms of colds caused by different viruses are slightly different. For example, coronaviruses are prone to myalgia, headaches and general discomfort. Parainfluenza virus and respiratory syncytial virus infections are more likely to cause fever, while coxsackievirus and coronavirus are also important pathogens that cause gastrointestinal symptoms. Viruses replicate in gastrointestinal tissues, causing pathological changes such as mucosal cell degeneration and necrosis, causing digestive system dysfunction, and symptoms such as nausea, vomiting, abdominal distension and diarrhea. Among them, coxsackievirus infection can be seen with fever (97%), pharyngitis (85%), vomiting (56%), headache (49%), respiratory signs and symptoms (44%), diarrhea (40%), abdominal pain (33%) and other respiratory and digestive system discomfort symptoms. Studies have shown that in addition to causing cold symptoms, another 57% of coronavirus patients will experience vomiting, diarrhea and abdominal pain, and children are more likely to experience gastrointestinal discomfort than adults. The above clinical syndrome caused by viral infection, with cold and gastrointestinal symptoms as the main manifestations, is often commonly referred to as "gastrointestinal cold" in my country. ICD10 does not have a classification for this disease name, and there is currently a lack of targeted treatment methods and unified efficacy evaluation standards. The clinical diagnosis is mainly based on exogenous symptoms and gastrointestinal symptoms, combined with blood routine and stool routine tests, but it needs to be differentiated from diseases such as viral gastroenteritis. Viral gastroenteritis is mainly caused by rotavirus, norovirus, enteric adenovirus and astrovirus involving the intestines. The lesions are localized, with watery diarrhea and abdominal pain as the first or main symptoms. Although both colds with gastrointestinal discomfort caused by viral infection and viral gastroenteritis involve digestive system symptoms, they have different pathogens and belong to two different types of diseases. At present, excessive use of antiviral drugs for colds significantly increases the risk of related adverse reactions. Therefore, most clinical treatments are symptomatic, such as acetaminophen, bisphenol pseudoephedrine tablets and other compound agents that have antipyretic and analgesic effects and reduce nasopharyngeal congestion and secretions, and decongestant drugs that relieve nasal catarrh symptoms such as nasal congestion and runny nose. However, the above drugs have not attracted enough attention for gastrointestinal symptoms associated with colds, or only probiotics are used to improve gastrointestinal function, and those with severe diarrhea are given antidiarrheal drugs such as montmorillonite powder, or oral rehydration salts and other drugs to correct water and electrolyte disorders to prevent dehydration. It can be seen that clinical treatment often uses a variety of drugs in combination for different symptoms, and the increase in medication dosage reduces patient compliance. At the same time, it increases the safety risks during the combined use of drugs. Therefore, it is still necessary to develop comprehensive and effective therapeutic drugs for colds with digestive system symptoms. Colds belong to the category of exogenous diseases in traditional Chinese medicine. The name of the disease "cold" was first seen in "Ren Zhai Zhi Zhi Fang" by Yang Shiying in the Song Dynasty. Traditional Chinese medicine believes that colds are caused by exogenous wind evil that invades the lung defense. In 2015, the "Guidelines for Diagnosis and Treatment of Common Colds in Traditional Chinese Medicine" issued by the Lung Disease Branch of the Chinese Association of Traditional Chinese Medicine classified the disease into: wind-cold syndrome, wind-heat syndrome, wind-dryness syndrome, summer-dampness syndrome, qi deficiency syndrome, and qi-yin deficiency syndrome. The "Expert Consensus on Diagnosis and Therapeutic Effect Evaluation of Gastrointestinal Colds" issued by the China Association of Traditional Chinese Medicine, the Lung Disease Branch of the Chinese Association of Traditional Chinese Medicine, and the Digestive Disease Committee of the World Federation of Chinese Medicine Societies classified the disease into exogenous wind-cold, gastrointestinal disharmony, exogenous summer-dampness, and gastrointestinal disharmony. It can be seen that wind evil is the primary pathogenic factor of exogenous diseases, and dampness blocking the middle is an important factor leading to gastrointestinal dysfunction. As early as the Spring and Autumn Period and the Warring States Period, "Huangdi Neijing" listed wind and dampness as the six pathogenic factors of exogenous pathogens. Zhang Zhongjing of the Eastern Han Dynasty's "Treatise on Febrile and Miscellaneous Diseases" clearly recorded exogenous diseases such as "stroke" and diseases caused by dampness in separate items. There were special chapters on "sunstroke" and "diseases caused by dampness", which laid the foundation for later generations to distinguish exogenous pathogens attacking the surface and damaging the stomach and intestines. In the Jin and Tang dynasties, doctors inherited the theories of the Inner Canon of Medicine and Treatise on Febrile and Miscellaneous Diseases, and adopted the method of expelling evil and relieving it externally for the treatment of wind and dampness. In the Song, Jin and Yuan dynasties, the understanding of wind and dampness in the exogenous pathogens was further deepened. The Taiping Huimin Hejijufang in the Song Dynasty included Huoxiang Zhengqi San, which is still a representative prescription for treating exogenous diseases with nausea, vomiting and diarrhea. In the Ming and Qing dynasties, Wu Jutong created Xinjia Xiangru Yin based on the prescription concept of "spicy and warm and spicy and cool", which has the effect of relieving the heat of depression and stopping dampness and nausea internally. Shi Shoutang created Huo Pu Xia Ling Tang based on the principle of "evil is resolved externally by sweating, and evil is resolved externally by defecation", to open the upper gate, open the branch river, and guide the dampness downward as a way out, so that the dampness is removed and the qi is unblocked, which plays a role in clearing dampness and heat in the upper, middle and lower three burners. It can be seen that colds with gastrointestinal discomfort can be attributed to wind evil attacking the surface and dampness accumulating in the middle. At present, Western medicine mainly administers drugs for respiratory tract infections, and only provides limited symptomatic treatment for gastrointestinal discomfort, with poor efficacy. Traditional Chinese medicine has accumulated rich experience in the diagnosis and treatment of such diseases and has created a series of representative treatment prescriptions. Therefore, it targets wind evil and dampness invading the human body, causing lung defense failure and gastrointestinal disharmony, leading to respiratory, For digestive comorbidities, developing innovative Chinese medicines based on the experience of doctors of all dynasties can provide new ideas for the treatment of this disease. For colds, Western medicine treatment mainly aims to relieve the respiratory and systemic discomfort symptoms caused by viral infections, but pays less attention to possible digestive tract discomfort symptoms. It often uses drugs to improve intestinal function, stop diarrhea, correct electrolyte disorders, etc., ignoring the overall nature of the disease. Therefore, the treatment effect for cold patients with both respiratory and digestive system symptoms is not ideal. (1) For symptoms such as fever, sore throat and body aches caused by colds: Commonly used antipyretic analgesics can reduce prostaglandin synthesis, cause peripheral vasodilation in the body temperature regulation center, induce sweating and heat dissipation, and block the impulses of pain nerve endings, thereby exerting anti-inflammatory, antipyretic and analgesic effects. Representative drugs include acetaminophen and ibuprofen, but excessive use of acetaminophen may cause liver damage, and ibuprofen often causes adverse reactions to the gastrointestinal system, aggravating gastrointestinal irritation symptoms such as nausea, vomiting and indigestion. (2) For common respiratory symptoms of colds such as nasal congestion and runny nose: Decongestants are commonly used to relieve symptoms such as nasal congestion and runny nose caused by colds by shrinking the swollen nasal mucosa and sinus blood vessels of cold patients. For example, pseudoephedrine selectively shrinks the blood vessels in the upper respiratory tract and is the most commonly used decongestant for cold patients. However, other vasoconstrictors such as ephedrine can cause side effects such as increased blood pressure if used in excess, so they should be used with caution. (3) For gastrointestinal dysfunction: Probiotics are commonly used to relieve symptoms of gastrointestinal dysfunction such as loss of appetite and diarrhea caused by colds. They repair damaged intestinal mucosa and eliminate inflammation, promote the growth of intestinal probiotics, inhibit harmful intestinal flora, and restore intestinal immune function and normal physiological function. Common drugs mainly include Clostridium butyricum and Enterococcus triple live bacteria, Bifidobacterium quadruple live bacteria, etc., but their effects are limited and only play an auxiliary role. (4) Antidiarrheal drugs: Montmorillonite powder is mostly used for acute and chronic diarrhea in adults and children. Montmorillonite powder is a new type of digestive tract mucosal protective agent. The microparticle powder can be evenly distributed on the surface of the gastrointestinal mucosa, has a certain fixation and inhibition effect on viruses and toxins in the intestine, and binds to mucus glycoproteins. Together, they can improve the mucosal barrier's defense function against attacking factors and the mucosal repair ability, promote rapid relief of symptoms, and reduce the frequency of diarrhea, but the effectiveness of single-drug treatment lasts a long time. (5) For electrolyte imbalance caused by dehydration: Oral rehydration salts are used to regulate water, electrolyte and acid-base balance, and are suitable for mild or moderate dehydration caused by various diarrhea. For patients with diarrhea, oral rehydration salts combined with conventional treatment have a synergistic effect on regulating the body's electrolyte balance, stabilizing the internal environment and promoting recovery. In summary, the clinical manifestations of patients with cold wind evil attacking the surface and dampness accumulation in the middle of the body often include respiratory and digestive tract discomfort, and the disease manifestations are more complicated. Therefore, the use of a single antipyretic and analgesic drug cannot achieve satisfactory results. It is necessary to use a variety of drugs with the functions of stopping diarrhea, correcting water and electrolyte disorders, and regulating intestinal function. The dosage is large and miscellaneous, and the integrity of disease treatment is ignored. Therefore, patient compliance is poor, which further indicates that Western medicine has obvious limitations in the treatment of cold wind evil attacking the surface and dampness accumulation in the middle of the body. Therefore, the clinic urgently needs safe and effective drugs with clinical characteristics to improve the treatment effect of colds accompanied by gastrointestinal discomfort. Summary of the invention The pharmaceutical composition of the present invention is the product of Professor Wu Yiling, an academician of the Chinese Academy of Engineering and director of the State Key Laboratory of Network Disease Research and Innovation of Traditional Chinese Medicine, who uses the network disease theory of traditional Chinese medicine to guide the research on lung diseases, and proposes the spatial transmission law of network diseases that the feeling of exogenous pathogens often follows the pathogenesis of "external (body surface yang network) - middle (meridians) - internal (visceral yin network)" from the outside to the inside. Combined with the view that the lung and the large intestine are exterior and interior, the lung, stomach and large intestine are connected by qi, and the invasion of the lung network by exogenous pathogens can often affect the pathogenesis of the spleen, stomach and intestines, three classic prescriptions of Huoxiang Zhengqi Powder in "Taiping Huimin Hejiju Fang" of the Song Dynasty, Huopu Xialing Decoction by Shi Shoutang of the Qing Dynasty and Xinjia Xiangru Yin in "Wenbing Tiaobian" by Wu Jutong, a master of febrile diseases, are selected and modified, and are used to treat cold wind evil attacking the surface and dampness accumulating in the middle, and it is proposed that exogenous wind evil accompanied by dampness is the root of the disease, and disharmony of the spleen, stomach and intestines is the core key. Wind evil invades the exterior of the body, and dampness attaches to the wind and fills the exterior and interior, causing dysfunction of the lung meridian, which in turn blocks the qi and clears the yang, and further leads to dysfunction of the spleen, stomach, intestines and viscera. The key to treatment is to "expel wind evil" and "transform dampness and eliminate filth", and to support the middle province. Based on this, the treatment method of "resolving the exterior and harmonizing the middle, eliminating filth and transforming dampness" is established. In response to wind evil and dampness causing disease, use pungent herbs to treat it. Aromatic drugs can dispel the evil and expel it from the exterior, harmonize the middle and eliminate dampness. Adding light and clear products can relieve the skin and the surface and remove heat, and combining with products that regulate qi, strengthen the spleen, dry dampness and promote dampness removal can enhance the effect of harmonizing the middle and eliminating dampness, which can effectively relieve fever, aversion to wind, nasal congestion and runny nose, headache, drowsiness, nausea and vomiting, diarrhea, heaviness of limbs, abdominal distension and pain, and poor appetite. The prescription of the pharmaceutical composition of the present invention draws on the prescription ideas of Huoxiang Zhengqi Powder and Huopu Xialing Decoction with pungent, warm, aromatic, warm and dry products to dissipate the external evil in the surface and dry the internal dampness and turbidity. For wind and dampness evil, Perilla leaf, Patchouli, Tangerine peel, Pinellia, Magnolia bark, Poria cocos, and ginger are selected. At the same time, according to the prescription idea of ​​"pungent and warm and pungent and cool" of Xinjia Xiangru Drink, Elsholtzia, Honeysuckle, and Forsythia in Xinjia Xiangru Drink are selected, and Scutellaria baicalensis is added. Perilla leaf is selected in the prescription to dispel the surface and dissipate evil, promote qi and harmonize the middle, Patchouli is pungent and warm to dissipate, dissipate the evil in the surface, and is fragrant to dispel filth, transform dampness and harmonize the middle. Elsholtzia has a clear smell and a light texture. It can promote lung qi and reach the skin and fur, and can reach the three burners and penetrate and remove dampness. Pinellia and Magnolia bark are used together to dry dampness and eliminate fullness, clear the middle burner qi mechanism, and play the effect of promoting qi and stopping vomiting. Tangerine peel and Poria cocos, when used together, can enhance the ability to eliminate dampness, penetrate dampness, and stop vomiting and diarrhea, while strengthening the spleen and stomach, and supporting the positive energy in the middle jiao. The original recipe of Huoxiang Zhengqi Powder uses ginger to harmonize the spleen and stomach to stop vomiting, and is used as an adjuvant. The above-mentioned pungent and warm aromatic drugs and bitter and dry products can eliminate external evil, eliminate dampness and turbidity internally, make the qi flow smoothly, harmonize the spleen and stomach, and heal all symptoms of the exterior and interior. In view of the characteristics that wind and dampness are easy to transform into heat and transmit, honeysuckle and forsythia are used to clear the heat of the lung meridian and the Wei division, penetrate the evil to the surface, and the medicinal properties are light and uplifting. Therefore, although they are heat-clearing drugs, they are not too bitter and cold to hinder the qi of the spleen and stomach. And Scutellaria baicalensis is good at clearing dampness and heat in the upper middle jiao, and has the effect of clearing dampness and turbidity and stagnation of heat in the body. Therefore, the selected prescription drugs after adding and subtracting the three classic prescriptions can not only eliminate the evil in the surface, but also harmonize the middle and eliminate filth, dry the internal dampness and turbidity, restore the clear yang of the qi, and make the body feel at ease. In the pharmaceutical composition of the present invention, the main drugs are perilla leaves and patchouli. Perilla leaf: pungent, warm, enters the lung and spleen meridians. Functions: dispel evil, dissipate pathogenic factors, promote qi and harmonize the middle. The medicinal properties are pungent and light, and its nature is light and dispersing. The aromatic taste is strong. It can open the upper part of the body, open the skin and fur, release the lung qi and open the pores. For diseases caused by wind and dampness, it is not limited to the drugs that can dissipate the symptoms, but the aromatic and dispersing products are used, which is also the "treatment". The upper burner is like a feather, which cannot be lifted unless it is light." In addition, the medicine enters the spleen meridian and runs through the middle burner, "opens the chest and diaphragm, wakes up the spleen and stomach, dissipates phlegm and fluid, relieves depression and benefits qi stagnation", and alleviates gastrointestinal symptoms such as anorexia and nausea. Patchouli: pungent, slightly warm, enters the spleen, stomach, and lung meridians. Functions: aromatic, dehumidifying, dispelling filth and harmonizing the middle. This product is light, warming and dispersing, pungent and warm, enters the lung meridian to regulate qi, enters the spleen and stomach to harmonize the middle, can both disperse and stimulate the defensive qi, and aromatic, dehumidifying and clearing the qi in the middle. Patchouli can open up the middle, nourish the lung meridian, and gradually replenish the positive qi. In the formula, perilla leaves and patchouli, two pungent and aromatic products, are used as the main medicines to relieve exogenous pathogens, overcome dampness and dispel filth. The assistant drugs are Elsholtzia ciliata, Magnolia officinalis, Scutellaria baicalensis and Pinellia ternata. Elsholtzia: pungent, slightly warm, enters the lung and stomach meridians. Functions: dispelling exterior pathogens, harmonizing the middle, dispelling dampness. In the treatment of exogenous wind pathogens with dampness, it is often used for its sweating and diuretic effects. This product is pungent, warm and aromatic. It can induce sweating, penetrate the muscles to dispel the pathogens on the surface, and diuretic can penetrate and dispel dampness in the middle jiao, treating both the exterior and the interior. Paired with the main drug Perilla leaf, it strengthens the function of dispelling exterior pathogens and dispelling dampness. When paired with Patchouli, it strengthens the effect of harmonizing the middle and dispelling dampness. Magnolia officinalis: bitter, pungent, warm, enters the spleen, stomach, lung, and large intestine meridians. Functions: promote qi and eliminate dampness, relieve fullness in the stomach. This medicine "warmth can dry dampness, pungent can clear phlegm, bitter can relieve qi", as a "medicine for relieving stagnation and pacifying stomach qi", targets the sluggish qi caused by dampness and turbidity, and the failure of the clear yang to rise, and plays the role of "digesting food and eliminating phlegm, removing dampness and dispersing swelling, and pacifying the earth and metal organs", and is matched with the main and auxiliary medicines, promoting qi and stopping vomiting in the pungent and warm products, and promoting the smooth flow of qi. Scutellaria baicalensis: bitter, cold, enters the lung, gallbladder, spleen, large intestine, and small intestine meridians. Functions: clearing heat and drying dampness. Scutellaria baicalensis is particularly good at clearing dampness and heat in the upper and middle jiao, and is good at treating pathogenic factors that have been stagnant for a long time and have turned into heat. Wind evil with dampness first attacks the surface. If the surface evil is not cleared in time, it will affect the gastrointestinal reception and conduction function, resulting in symptoms such as vomiting, nausea, acid reflux, diarrhea, and bowel sounds. In order to target the phenomenon of internal dampness and heat, "Scutellaria baicalensis cannot be used to clear the accumulation." Adding cold herbs to the pungent and warm herbs in the prescription also takes the essence of Wu Jutong's prescription composition of "pungent and warm and pungent and cool". Banxia: pungent, warm, enters the spleen, stomach, and lung meridians. Functions: drying dampness and harmonizing the stomach, lowering adverse qi and stopping vomiting. Banxia can nourish the spleen, dry out dampness and transport water, especially good at drying out dampness and turbidity in the middle jiao, and has the effect of "opening the appetite and strengthening the spleen, stopping vomiting, and removing phlegm in the chest". It exerts its pungent, warm and dispersing properties to dredge the qi. The above four herbs are ministerial herbs. Elsholtzia is pungent, warm and aromatic, and can dispel the pathogens in the exterior to relieve the symptoms of the exterior. It is used together with Magnolia officinalis to dry and remove dampness and turbidity in the middle jiao to treat vomiting and diarrhea. It is combined with Scutellaria baicalensis, which has strong heat-clearing ability, to warm and dispel dampness and turbidity and clear stagnant heat. Pinellia is pungent and warm, enters the lungs and stomach, and can reduce adverse reactions and harmonize the stomach. Magnolia officinalis is bitter, pungent and warm, and can dry dampness and dispel fullness, regulate qi and smooth the middle jiao. The combination of the two can enhance the effects of clearing the qi mechanism in the middle jiao and stopping vomiting. The adjuvant drugs are honeysuckle, forsythia, poria and tangerine peel. Honeysuckle: sweet, cold, enters the lung, heart, and stomach meridians, functions to clear away wind evil, and penetrate evil to the surface. Honeysuckle and honeysuckle belong to the same thing in ancient books. In the 2020 edition of the "Chinese Pharmacopoeia", the two herbs have the same nature, flavor, meridians, functions, indications, usage and dosage. The two herbs have the same pharmacology and medicinal properties. This product is good at dispersing external evil to the surface, and is used with Forsythia suspensa, and Forsythia suspensa and flowers are used together to clear away the stagnant heat in the lungs, lead the heat evil to penetrate the skin surface and resolve it, without hindering the middle qi. Forsythia suspensa: bitter, slightly cold, enters the lung, heart, and small intestine meridians, functions to relieve the skin and clear the internal heat. It can disperse the evil from the upper part of the body, and its slightly cold nature can prevent the external evil from entering the body and turning into heat, but it will not be too cold to hinder the clear yang. When used with Scutellaria baicalensis, it can also clear the internal heat and make the heat evil go out from the inside. Poria: sweet, light, neutral, enters the heart, lung, spleen, and kidney meridians. It has the functions of strengthening the spleen and harmonizing the middle, dispelling dampness and stopping diarrhea, and can relieve the spleen and stomach related symptoms such as nausea, vomiting, and loss of appetite caused by internal dampness. The medicinal properties are mild, nourishing but not greasy, and beneficial but not strong. This medicine can take into account both strengthening the body and expelling evil, and can strengthen the effect of dispelling dampness by replenishing the deficiency of the middle jiao. Tangerine peel: bitter, pungent, warm, belongs to the lung and spleen meridians, has the function of regulating qi and strengthening the spleen, drying dampness and stopping vomiting. It is a good medicine for treating qi failure caused by lung and spleen stagnation and heat. Tangerine peel can also relieve qi and stop vomiting for digestive tract symptoms such as nausea, loss of appetite, diarrhea, etc. caused by spleen and stomach dampness stagnation and dysfunction of transportation and transformation. Bitterness can purge and dry, pungent can disperse, and warmness can harmonize. Its treatment of all diseases always takes its function of regulating qi and drying dampness. It can tonify with tonic medicine, purge with laxative medicine, raise with ascending medicine, and lower with descending medicine. The spleen is the mother of the original qi, and the lung is the flute of the qi, so tangerine peel is a medicine for the qi of the two meridians, but it can tonify, purge, rise and fall according to the combination. The above four herbs are adjuvants. Honeysuckle is sweet and cold, with a fragrant smell, which can clear away evil and reach the surface; Forsythia suspensa is bitter and slightly cold, and can clear heat from the inside. "Forsythia suspensa and honeysuckle are used to take their pungent and cool properties to reach the surface of the lung meridian, and they are purely from the outside, not "It must go to the middle", Lian and Hua are used together, which are light, clear, ascending, floating and dispersing, and can not only penetrate the heat and relieve the exterior, but also clear the heat inside. Tangerine peel is matched with Magnolia officinalis to strengthen the function of regulating qi and harmonizing the middle, and with Pinellia ternata, it can play the effect of harmonizing the middle and stopping vomiting, and with Poria cocos, it can help to eliminate dampness and stop diarrhea, and also support the positive energy of the middle jiao. Assistant medicine: ginger. Ginger: pungent, slightly warm, enters the lung, spleen, and stomach meridians, has the functions of dispelling pathogens, stopping vomiting and harmonizing the stomach. Ginger removes dampness, warms the stomach and benefits the spleen and stomach. When the spleen and stomach qi are warm and healthy, dampness will naturally go away. It is used as a guiding drug to complement the whole prescription. This prescription uses a lot of pungent and aromatic products to disperse and dispel the exterior, dispel dampness and harmonize the middle, and can protect the middle qi and prevent the turbid evil from staying for a long time. The pungent taste is mobile and good at dispersing and promoting qi. As Ye Tianshi said, "the network is drained by pungent", the use of a large number of pungent and aromatic drugs in the prescription can smooth the lung network qi and help the recovery of lung network function. At the same time, bitter drugs are used to enhance the effect of drying and removing dampness and turbidity. The combination of pungent and warm antipyretic drugs and pungent and cool heat-clearing drugs can not only dispel dampness, but also clear and resolve the internal heat, playing the dual effects of external penetration and internal clearing, but not too much dispersion may cause changes. The whole prescription disperses the evil of the lung and the muscle surface, and internalizes the dampness and turbidity retained in the middle and lower Jiao, so that the rheumatism and combined evil on the surface can be warmed and dispersed, and when it enters the interior, it can first dispel the evil and penetrate the inside to the outside, and secondly, it can lightly penetrate and lead the evil downward. The whole prescription takes both the exterior and the interior into consideration, uses both warm and cool, and strengthens the body to dispel evil, and plays the effect of dispersing the exterior and harmonizing the middle, and removing filth and dampness. The whole prescription has both promoting the flow of qi and benefiting the body, harmonizing the middle and eliminating filth. The combination of various medicines can eliminate the external and internal evils. Those in the upper part of the lungs and the defense system can be eliminated by penetrating the surface, and those in the middle and lower parts of the stomach and intestines can be eliminated by drying them out and penetrating the body. This prescription is derived from a famous Chinese medicine prescription. The etiology and pathogenesis, treatment principles and methods, prescriptions and medicines are consistent, with a high degree of fit and a reasonable prescription. It has the effects of dispelling the exterior, harmonizing the middle, eliminating filth and eliminating dampness. It is a Chinese medicine preparation with definite efficacy and safe to take developed based on clinical experience. It can fill the blank in the treatment of colds with wind evil and dampness as the main manifestations of Chinese patent medicine. Pharmacological studies have shown that the pharmaceutical composition of the present invention has a significant inhibitory effect on Coxsackie virus (CVB3), influenza A virus (H3N2), influenza B virus (IBV), respiratory syncytial virus (RSV), enterovirus (EV71), coronavirus (HCoV-229E), parainfluenza virus (PIV), and rotavirus (RV) in vitro. It also has the effects of regulating the balance of immune cells and reducing local tissue inflammatory reactions. The pharmaceutical composition of the present invention also has obvious effects of inhibiting gastric emptying and intestinal motility, stopping diarrhea, relieving fever, relieving pain and anti-inflammation, and relieving clinical symptoms caused by viruses. The inventor conducted a small sample clinical study of 90 patients with cold (wind evil attacking the surface, dampness accumulation in the middle block syndrome) and suggested that the clinical cure rate of patients treated with the pharmaceutical composition of the present invention was significantly higher than that of the control group, and showed a good trend of efficacy in shortening the course of disease and relieving symptoms. In summary, the pharmaceutical composition of the present invention will produce a good therapeutic effect benefit on cold (wind evil attacking the surface, dampness accumulation in the middle block syndrome) in clinical trials. In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions: A traditional Chinese medicine composition with the effect of treating colds, the traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 230-340 parts of perilla leaves, 230-340 parts of patchouli, 230-340 parts of elsholtzia, 230-340 parts of magnolia bark, 230-340 parts of scutellaria, 170-260 parts of pinellia tuber, 285-430 parts of honeysuckle, 230-340 parts of forsythia, 230-340 parts of poria, 230-340 parts of tangerine peel, and 115-170 parts of ginger. Furthermore, the Chinese medicine composition with the effect of treating colds is composed of the following raw materials in parts by weight: 230 parts of perilla leaves, 340 parts of patchouli, 230 parts of Elsholtzia, 340 parts of Magnolia officinalis, 230 parts of Scutellaria baicalensis, 260 parts of Pinellia ternata, 285 parts of Lonicera japonica, 340 parts of Forsythia suspensa, 230 parts of Poria cocos, 340 parts of dried tangerine peel, and 115 parts of ginger. Furthermore, the Chinese medicine composition with the effect of treating colds is composed of the following raw materials in parts by weight: 340 parts of perilla leaves, 230 parts of patchouli, 340 parts of Elsholtzia, 230 parts of Magnolia officinalis, 340 parts of Scutellaria baicalensis, 170 parts of Pinellia ternata, 430 parts of Lonicera japonica, 230 parts of Forsythia suspensa, 340 parts of Poria cocos, 230 parts of dried tangerine peel, and 170 parts of ginger. Furthermore, the Chinese medicine composition with the effect of treating colds is composed of the following raw materials in parts by weight: 300 parts of perilla leaves, 300 parts of patchouli, 300 parts of Elsholtzia, 300 parts of Magnolia officinalis, 300 parts of Scutellaria baicalensis, 230 parts of Pinellia ternata, 380 parts of Lonicera japonica, 300 parts of Forsythia suspensa, 300 parts of Poria cocos, 300 parts of dried tangerine peel, and 150 parts of ginger. Furthermore, the Chinese medicine composition with the effect of treating colds is composed of the following raw materials in parts by weight: 286 parts of perilla leaves, 286 parts of patchouli, 286 parts of Elsholtzia, 286 parts of Magnolia officinalis, 286 parts of Scutellaria baicalensis, 214 parts of Pinellia ternata, 357 parts of Lonicera japonica, 286 parts of Forsythia suspensa, 286 parts of Poria cocos, 286 parts of dried tangerine peel, and 143 parts of ginger. Furthermore, the Chinese medicine composition with the effect of treating colds is composed of the following raw materials in parts by weight: 250 parts of perilla leaves, 250 parts of patchouli, 250 parts of Elsholtzia, 250 parts of Magnolia officinalis, 250 parts of Scutellaria baicalensis, 200 parts of Pinellia ternata, 320 parts of Lonicera japonica, 250 parts of Forsythia suspensa, 250 parts of Poria cocos, 250 parts of dried tangerine peel, and 125 parts of ginger. Furthermore, the cold treated by the Chinese medicine composition of the present invention is at least one of influenza, common cold or gastrointestinal cold. The present invention provides the use of the above-mentioned traditional Chinese medicine composition in preparing anti-H3N2, IBV, RSV, CVB3, EV71, HCoV-229E, PIV or RV virus drugs. The present invention provides the use of the above-mentioned traditional Chinese medicine composition in preparing a drug for inhibiting the replication of Coxsackievirus B3 in large intestine tissue, regulating the balance of immune cells, and reducing local tissue inflammatory response. The present invention provides the use of the above-mentioned traditional Chinese medicine composition in preparing a drug for reducing the degree of colon lesions, increasing the ratio of CD4+ / CD8+ lymphocytes in blood, reducing the level of TNF-α in the large intestine tissue of model animals, and increasing the level of IFN-γ. The present invention provides application of the above-mentioned traditional Chinese medicine composition in preparing a medicine for inhibiting gastric emptying and intestinal motility. The present invention provides application of the above-mentioned traditional Chinese medicine composition in preparing medicine for treating diarrhea. The present invention provides application of the above-mentioned traditional Chinese medicine composition in preparing analgesic drugs. The present invention provides application of the above-mentioned traditional Chinese medicine composition in preparing anti-inflammatory drugs. Furthermore, the gastrointestinal cold treated by the Chinese medicine composition of the present invention is manifested by fever, aversion to wind, headache, drowsiness, nausea and vomiting, diarrhea, nasal congestion and runny nose, heaviness in limbs, abdominal distension and pain, or poor appetite. Furthermore, the preparation method of the Chinese medicine composition of the present invention comprises: the active ingredients thereof are prepared by the following steps: (1) Weighing perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use, and filtering the aqueous solution after distillation for later use; (2) Weighing Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Lonicera japonica, Forsythia suspensa, and Poria cocos according to the prescribed amount, extracting with water, filtering, concentrating the filtrate and the aqueous solution after distillation in step (1) under reduced pressure, spray drying, collecting the spray powder and setting aside; The volatile oil obtained in step (1) and the extract obtained in step (2) together constitute the active ingredient of the traditional Chinese medicine composition. Furthermore, the present invention provides a medicine, which includes the Chinese medicine composition as described above or the Chinese medicine composition prepared by the preparation method as described above. The dosage form of the drug protected by the present invention is capsule, tablet, granule, injection, pill, powder or oral solution. In order to realize the above dosage forms, pharmaceutically acceptable excipients need to be added when preparing these dosage forms, such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, etc. Fillers include starch, pregelatinized starch, lactose, mannitol, chitosan, microcrystalline cellulose, sucrose, etc.; disintegrants include starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, etc.; lubricants include magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agents include polyvinyl pyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, etc.; binders include starch slurry, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, etc.; sweeteners include sodium saccharin, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, etc.; flavoring agents include sweeteners and various flavors; preservatives include parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroethidine acetate, eucalyptus oil, etc.; matrices include PEG6000, PEG4000, insect wax, etc. Furthermore, the granules of the Chinese medicine composition of the present invention are prepared by the following steps: (1) Weighing perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) Weighing the prescribed amount of Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Honeysuckle, Forsythia suspensa, and Poria cocos, adding water to boil, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound; (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), and granulate them to prepare granules according to conventional methods. Furthermore, the preparation method of the granules of the Chinese medicine composition of the present invention is: (1) Weighing perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, adding 8-12 times the amount of water, and extracting volatile oil by steam distillation for 6-10 hours, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) Weighing the prescribed amount of Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Honeysuckle, Forsythia suspensa, and Poria cocos, adding 8-12 times the amount of water and boiling twice, each time for 1-2 hours, filtering, combining the filtrate with the volatile oil extract of step (1), concentrating under reduced pressure, and spray drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which is dried and crushed for later use; (4) The dry paste powder obtained in step (2) and the volatile oil inclusion compound dry powder obtained in step (3) are granulated by dry method to prepare granules according to conventional methods. Furthermore, the preparation method of the granules of the Chinese medicine composition of the present invention is: (1) Weighing the perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, adding 10 times the amount of water, and extracting the volatile oil by steam distillation for 8 hours, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain the volatile oil extract for later use; (2) Weighing the prescribed amount of Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Honeysuckle, Forsythia suspensa, and Poria cocos, adding 10 times the amount of water and boiling twice, each time for 1.5 hours, filtering, combining the filtrate with the volatile oil extract of step (1), concentrating under reduced pressure, and spray drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which is dried and crushed for later use; (4) The dry paste powder obtained in step (2) and the volatile oil inclusion compound dry powder obtained in step (3) are granulated by dry method to prepare granules according to conventional methods. Furthermore, the tablets of the Chinese medicine composition of the present invention are prepared by the following steps: (1) Weighing the perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, adding 10 times the amount of water, and extracting the volatile oil by steam distillation for 8 hours, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain the volatile oil extract for later use; (2) Weighing the prescribed amount of Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Honeysuckle, Forsythia suspensa, and Poria cocos, adding 10 times the amount of water and boiling twice, each time for 1.5 hours, filtering, combining the filtrate with the volatile oil extract of step (1), concentrating under reduced pressure, and spray drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which is dried and crushed for later use; (4) The dry paste powder obtained in step (2) and the volatile oil inclusion compound dry powder obtained in step (3) are granulated by dry method and prepared into tablets according to conventional methods. Furthermore, the preparation method of the capsule of the Chinese medicine composition of the present invention is: (1) Weighing the perilla leaves, patchouli, elsholtzia, tangerine peel, and ginger according to the prescribed amount, adding 10 times the amount of water, and extracting the volatile oil by steam distillation for 8 hours, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain the volatile oil extract for later use; (2) Weighing the prescribed amount of Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Honeysuckle, Forsythia suspensa, and Poria cocos, adding 10 times the amount of water and boiling twice, each time for 1.5 hours, filtering, combining the filtrate with the volatile oil extract of step (1), concentrating under reduced pressure, and spray drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which is dried and crushed for later use; (4) The dry paste powder obtained in step (2) and the volatile oil inclusion compound dry powder obtained in step (3) are granulated by dry method and prepared into capsules according to conventional methods. Furthermore, the present invention also provides a method for treating a disease, which comprises administering the Chinese medicine composition as described above, or administering the Chinese medicine composition prepared by the preparation method as described above, or administering the drug as described above in the claims. The treatment comprises at least one of the following: treating colds, inhibiting gastric emptying and intestinal motility, treating diarrhea, relieving pain and / or anti-inflammation. The cold includes influenza, common cold or gastrointestinal cold. The gastrointestinal cold is manifested by fever, aversion to wind, headache, drowsiness, nausea and vomiting, diarrhea, nasal congestion and runny nose, heaviness in limbs, abdominal distension and pain, or poor appetite. The treatment of colds includes: fighting H3N2, IBV, RSV, CVB3, EV71, HCoV-229E, PIV or RV viruses. The treatment of colds comprises at least one of the following: Inhibit the replication of Coxsackievirus B3 in large intestine tissue, regulate the balance of immune cells, and reduce local tissue inflammatory response; It reduces the degree of colon lesions, increases the ratio of CD4+ / CD8+ lymphocytes in the blood, reduces the level of TNF-α in the large intestine tissue of model animals, and increases the level of IFN-γ. The method for preparing the active ingredients of the traditional Chinese medicine composition provided by the present invention has simple process, convenient operation, safety and environmental protection, and can retain the active ingredients in the traditional Chinese medicine to the greatest extent, thereby ensuring the efficacy of the medicine. DETAILED DESCRIPTION In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. In order to better illustrate the Chinese medicine composition with the efficacy of treating colds provided by the embodiments of the present invention, further examples are given below. Example 1 prescription: Preparation method: The above eleven herbs, including perilla leaf, patchouli, elsholtzia, tangerine peel and ginger, are added with 10 times the amount of water, and the volatile oil is extracted by steam distillation for 8 hours. The volatile oil is collected and set aside. The distilled aqueous solution is filtered and set aside; the remaining six herbs, including Magnolia officinalis, are added with 10 times the amount of water and decocted twice, each time for 1.5 hours, filtered, and the filtrate and the distilled aqueous solution are concentrated under reduced pressure, spray-dried, and the spray powder is collected and set aside; the volatile oil is included in 10 times the amount of beta-cyclodextrin, the inclusion compound is dried and crushed, the spray powder, the inclusion compound, sucralose and maltodextrin are mixed, and granulated by dry method to make 1000g granules. Example 2 prescription: Preparation method: The above eleven herbs, including perilla leaf, patchouli, elsholtzia, tangerine peel and ginger, are added with 8 times the amount of water, and the volatile oil is extracted by steam distillation. The extraction is carried out for 10 hours, and the volatile oil is collected and set aside. The aqueous solution after distillation is filtered and set aside; the remaining six herbs such as Magnolia officinalis are added with 8 times the amount of water and decocted twice, each time for 2 hours, filtered, and the filtrate and the aqueous solution after distillation are concentrated under reduced pressure, spray-dried, and the spray powder is collected and set aside; the volatile oil is included in 10 times the amount of beta-cyclodextrin, the inclusion compound is dried and crushed, the spray powder, the inclusion compound, sucralose and maltodextrin are mixed, dry granulated to make 1000 g of granules, and tablets are made according to the conventional method. Example 3 prescription: Preparation method: The above eleven herbs, including perilla leaf, patchouli, elsholtzia, tangerine peel and ginger, are added with 12 times the amount of water, and the volatile oil is extracted by steam distillation for 10 hours. The volatile oil is collected and set aside. The aqueous solution after distillation is filtered and set aside; the remaining six herbs, including Magnolia officinalis, are decocted twice with 8 times the amount of water, each time for 1 hour, filtered, and the filtrate and the aqueous solution after distillation are concentrated under reduced pressure, spray-dried, and the spray powder is collected and set aside; the volatile oil is included in 10 times the amount of beta-cyclodextrin, the inclusion compound is dried and crushed, the spray powder, inclusion compound, sucralose and maltodextrin are mixed, dry granulated to make 1000 g of granules, and made into capsules according to the conventional method. Example 4 prescription: Preparation method: The above eleven herbs, including perilla leaf, patchouli, elsholtzia, tangerine peel and ginger, are added with 10 times the amount of water, and the volatile oil is extracted by steam distillation for 8 hours. The volatile oil is collected and set aside. The distilled aqueous solution is filtered and set aside; the remaining six herbs, including magnolia bark, are decocted twice with 10 times the amount of water, each time for 1.5 hours, filtered, and the filtrate and the distilled aqueous solution are concentrated under reduced pressure, spray-dried, and the spray powder is collected and set aside; the volatile oil is included with 10 times the amount of beta-cyclodextrin, the inclusion compound is dried and crushed, the spray powder, the inclusion compound, sucralose and maltodextrin are mixed, and made into pills according to the conventional method. Example 5 prescription: Preparation method: The above eleven ingredients, including perilla leaf, patchouli, elsholtzia, tangerine peel and ginger, are added with 10 times the amount of water and the volatile oil is extracted by steam distillation for 8 hours. The volatile oil is collected and set aside. The distilled aqueous solution is filtered and set aside. The remaining six ingredients including Magnolia officinalis are added with 10 times the amount of water and decocted twice, each time for 1.5 hours, filtered, and the filtrate and the distilled aqueous solution are concentrated under reduced pressure and made into oral solution according to the conventional method. In order to better illustrate the characteristics of the Chinese medicine composition with the efficacy of treating colds provided in the embodiments of the present invention, the particles of the embodiments are tested for their effects. Test Example 1 In order to illustrate the safety and in vitro antiviral effect of the Chinese medicine composition of the present invention, the granules prepared in Example 1 (hereinafter referred to as the Chinese medicine composition of the present invention) were used to conduct toxicity tests and in vitro antiviral tests. 1 Study Objectives This experiment investigates the in vitro antiviral effects of the pharmaceutical composition of the present invention on influenza A virus (H3N2), influenza B virus (IBV), respiratory syncytial virus (RSV), rhinovirus (Rhv), coxsackievirus (CVB3), enterovirus (EV71), coronavirus (HCoV-229E), parainfluenza virus (PIV) and rotavirus (RV), to provide a reference for its clinical research. 2 Test materials 2.1 Test substances The pharmaceutical composition of the present invention, batch number: 211101, content: 4.5g crude drug per gram of powder, valid until: 2023.11.09. Usage and dosage: oral, 0.5g crude drug / kg, provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd. 2.2 Positive Control Oseltamivir acid, batch number: 18345; produced by MedChem Express, validity period: valid for 6 months after preparation at -80℃, valid for 1 month at -20℃; used as a positive control drug for influenza A virus (H3N2) and influenza B virus (IBV); Ribavirin spray, 400 mg / bottle, Penglai Nuokang Pharmaceutical Co., Ltd., batch number: 210720, validity period: 2023.07.19; used as a positive control drug for respiratory syncytial virus (RSV), rhinovirus (Rhv), coxsackievirus (CVB3), enterovirus (EV71), rotavirus (RV) and parainfluenza virus (PIV); recombinant human interferon α2b gel, specification 1.0×10 5 IU / gram, 5g / tube, Zhaoke Pharmaceutical (Hefei) Co., Ltd., batch number: 20210821, expiration date: 2023.02.27; positive drug for coronavirus (HCoV-229E). 2.3 Virus strains Influenza A virus (H3N2, strain A / California / 2 / 2014), number: ATCC VR-1938, purchased from ATCC, USA; influenza B virus (IBV, B / Virginia / ATCC5 / 2012), number: ATCC VR-1807, purchased from ATCC, USA; rhinovirus (Rhv, 130-63 [V-185-001-021]), number: ATCC VR-1187; respiratory syncytial virus (RSV, Long), number: ATCC VR-26PQ; coxsackie virus (CVB3, Nancy), No.: ATCC VR-30; Enterovirus (EV71, H), No.: ATCC VR-1432; Coronavirus (HCoV-229E, 229E), No.: ATCC VR-740; Parainfluenza virus (PIV, ATCC-2011-5), No.: ATCC VR-1782; Rotavirus (RV, Hu / Australia / 10-25-10 / 77 / L), No.: ATCC VR-2104; all from ATCC, USA. All are cultured and preserved in our company's Class II biosafety laboratory, laboratory registration number: Changweijianshibeizi (2021) No. B010. 2.4 Cell lines African green monkey kidney cells (Vero), canine kidney cells (MDCK), human laryngeal epidermoid carcinoma cells (HEp-2), human embryonic lung cells (MRC-5), and monkey kidney cells (LLC-MK2) were obtained from Wuhan Pronocell Life Science Co., Ltd. Human cervical cancer cells (H1HeLa) were obtained from Beijing Beina Chuanglian Biotechnology Research Institute. 2.5 Main Reagents The main reagents are shown in Table 1 below. Table 1 Reagent list 2.6 Main instruments BSCIIB2-1101 biological safety cabinet, produced by Shanghai Ruiyang Purification Equipment Co., Ltd.; YXQ-50A vertical pressure steam sterilizer, produced by Shanghai Boxun Medical Biological Instrument Co., Ltd.; 3111 CO2 incubator, produced by Thermo Fisher, USA; CJ-1F medical clean bench, produced by Suzhou Fengshi Experimental Animal Equipment Co., Ltd.; SW-CJ-1FD clean Clean workbench, produced by Suzhou Antai Air Technology Co., Ltd. of Sujing Group; DMi8 inverted fluorescence microscope, produced by Leica of Germany. 3. Test content 3.1 Preparation of culture medium 3.1.1 Preparation of complete cell culture medium Add FBS at a final concentration of 10% to the DMEM medium, mix well, and store at 2-8°C for later use. 3.1.2 Preparation of virus maintenance solution Serum-free DMEM medium (for Rhv and PIV virus culture); DMEM medium + 2μg / mL TPCK-treated trypsin (for H3N2 and IBV virus culture); DMEM medium containing 2% FBS (for RSV, CVB3, EV71, and HCoV-229E virus culture); DMEM medium + 1μg / mL Trypsin (for RV virus culture). 3.2 Cell culture African green monkey kidney cells (Vero), canine kidney cells (MDCK), human laryngeal epidermoid carcinoma cells (HEp-2), human embryonic lung cells (MRC-5), monkey kidney cells (LLC-MK2), and human cervical cancer cells (H1HeLa) are all adherent growth cells. DMEM medium containing 10% FBS is selected for culture. The culture method is as follows: take a single layer of adherent growth cells, discard the medium, wash twice with 1×PBS, then add 1mL 0.25% Trypsin-EDTA for digestion, let it stand in an incubator for 2-5min, observe under a microscope, the cells become round and are about to fall off, add 3mL complete medium to stop digestion, gently blow to form a single cell suspension, and transfer to an EP tube, centrifuge at 1000rpm for 5min, discard the supernatant, add an appropriate amount of fresh complete medium to resuspend, inoculate into a new culture bottle according to a certain ratio, and place it in a 37°C, 5% CO2 incubator for culture. According to the cell growth, passage is performed every 2-3d. 3.3 Cytotoxic effects of the pharmaceutical composition of the present invention (1) Experimental grouping: According to the references, appropriate drug initial concentrations were selected for experimental grouping. All drugs were diluted in serum-free DMEM medium. Serum DMEM medium; test group, the concentration of the pharmaceutical composition of the present invention is 1000, 333.33, 111.11, 100, 33.33, 11.11 μg / mL; positive control drug group, the concentration of positive drug oseltamivir acid is 1000, 500, 250, 125, 62.5, 31.25 μM; the final concentration of positive drug ribavirin is 1000, 333.33, 111.11, 100, 33.33, 11.11 μg / mL; the final concentration of positive drug recombinant human interferon α2b gel is 1000, 333.33, 111.11, 100, 33.33, 11.11 IU / mL. Blank control group: only serum-free DMEM medium, no cells. Three replicates are set for each concentration in each group. (2) Cell plating: Prepare cells into 1×10 4 The single-cell suspension of 100 μL / mL was inoculated into a 96-well cell culture plate at 100 μL / well and incubated overnight in a 37°C, 5% CO2 incubator. (3) Drug addition test: The culture medium was discarded and the cells were washed twice with 1× PBS. 100 μL / well of the culture medium containing different concentrations of drugs was added to each test group and cultured in a cell culture incubator at 37°C and 5% CO2 for 72 h. Then 10 μL of CCK8 was added to each well. After incubation in the incubator for 1 to 4 h, the OD was read on a microplate reader. 450nm The cell inhibition rate and the half inhibitory concentration (IC 50 ). Inhibition rate (%) = (average OD of cell control group 450nm Value - average OD of drug group 450nm value) / (average OD of cell control group 450nm value)×100% 3.4 Virus amplification Host cells MDCK, H1HeLa, HEp-2, LLC-MK2, MRC-5 and Vero were inoculated into culture flasks respectively. When the cell confluence reached 70% to 80%, the culture medium was discarded, the cells were washed twice with 1×PBS, and then 1 mL of virus solution was added to the T25 culture flask and incubated in an incubator. The culture plate was gently shaken every 15 to 30 minutes to allow the virus to adsorb evenly on the cell surface. After 2 hours, the virus solution was discarded, and the cells were washed twice with 1×PBS to wash away the free virus. Then, an appropriate amount of virus maintenance solution was added and the cells were placed in an incubator for continued culture. The specific culture conditions are shown in Table 2. The cell morphology was observed under an inverted microscope every day. When 80% to 100% of the cells were swollen and rounded, the intercellular space increased, the nuclei were condensed or ruptured, and in severe cases, the cells partially or completely fell off, the culture was stopped and repeated freezing and thawing was adopted. The cells were broken and centrifuged at 3000 rpm for 10 min. The supernatant was collected and dispensed into cryopreservation tubes for the next test or ultra-low temperature storage for future use. Table 2 Correspondence between viruses, host cells and culture conditions 3.5 TCID 50 ) The virus solution collected in 3.3 was subjected to TCID 50 The specific method for determination is as follows: (1) Cell plating: Vero, MDCK, HEp-2, MRC-5, LLC-MK2, and H1HeLa cells were prepared into 1×10 4 The single-cell suspension of 100 μL / mL was inoculated into a 96-well cell culture plate at 100 μL / well and incubated overnight in a 37°C, 5% CO2 incubator. (2) Virus inoculation: After the cells grew to a monolayer of adherent cells, the virus stock solution was diluted 10-fold with DMEM medium to 6 concentrations, 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 8 replicate wells and 2 replicate wells for cell control were set for each concentration. The original culture medium in the 96-well plate was discarded, and the plate was washed twice with 1× PBS solution, and then 100 μL of virus dilution of the corresponding concentration was added to each well. (3) Culture observation: After virus inoculation, place the 96-well cell culture plate in an incubator with corresponding culture conditions and incubate for 2 hours. Take out the culture plate and gently shake it every 30 minutes to promote virus adsorption. After 2 hours of adsorption, replace each well with 100 μL of virus maintenance solution and continue culturing. Then observe the cytopathic effect under an inverted microscope every day, and record the number of wells with CPE. The end point is when no lesions appear at the highest dilution, and calculate TCID according to the Reed-Muench formula. 50 : TCID 50 = The highest logarithm of virus dilution with CPE higher than 50% + distance ratio × logarithm of dilution multiple Wherein, distance ratio value = (percentage above 50% CPE - 50%) / (percentage above 50% CPE - percentage below 50% CPE). 3.6 In vitro antiviral effect of the pharmaceutical composition of the present invention (1) Experimental grouping: comprehensive cytotoxicity test results and OD 450nm The concentration was set based on the literature reports on the antiviral effects of the positive drug and the control drug. The concentration level with no obvious toxic effect on cells under the microscope was selected as the starting concentration of the in vitro antiviral test. The test drug composition of the present invention was diluted 2 times, the positive control drug oseltamivir acid was diluted 4 times, and the other drugs were diluted 2 times. All were diluted to 5 concentrations, and 4 replicates were set for each concentration. The virus titer was selected as 100 TCID 50 The cells were infected and divided into the following groups: virus + drug group, where the drug group was the test substance group and the positive control drug group, virus control group (with virus but no drug), and cell control group (with only virus maintenance solution). Specific information is shown in Table 3 below. (2) Cell plating: Prepare cells into 1×10 4 The single-cell suspension of 100 μL / mL was inoculated into a 96-well cell culture plate at 100 μL / well and incubated overnight in a 37°C, 5% CO2 incubator. (3) Drug addition observation: Discard the culture medium, wash twice with 1× PBS, and add 100 TCID 50 50 μL of virus solution was added per well, adsorbed for 2 h, the virus solution was discarded, and the cells were washed twice with 1× PBS. Then, 100 μL of culture medium containing different concentrations of drugs was added according to the above group settings and culture was continued. (4) Observe the cytopathic effect (CPE). When the CPE of the virus control group is about 75%, terminate the culture. Add 10 μL of CCK8 to each well and incubate for 1 to 4 h. Measure the cell OD on a microplate reader. 450nm The inhibition rate of the test substance at different concentrations on the virus and the half effective concentration (EC 50 ). Virus inhibition rate (%) = [mean OD of drug treatment group (drug + virus) 450nm Value - Average OD of virus control group 450nm value] / [average OD of cell control 450nm Value - Average OD of virus control group 450nm value] × 100%, Therapeutic index TI = cytotoxicity IC 50 / in vitro antiviral EC 50 . Table 3 In vitro antiviral drug concentration and viral infection dose 4. Data processing and information analysis All data in this experimental summary report were rounded off, and the values ​​that were not divisible were retained to two decimal places. The original data were statistically analyzed using Excel 2010 and the inhibition rate was calculated according to the corresponding formula. Then, the IC was obtained by curve fitting using GraphPad Prism8.0.1 software based on the inhibition rate. 50 or EC 50 . 5 Test results 5.1 Cytotoxicity results of the pharmaceutical composition of the present invention As shown in Table 4, the IC values ​​of the in vitro toxicity of the pharmaceutical composition of the present invention to MDCK cells are 50 It was 321.20μg / mL; the rest were greater than 1000μg / mL. In subsequent experiments, the drug concentration that had no obvious toxicity to cells under a microscope was selected as the starting concentration for in vitro antiviral tests. Table 4 In vitro cytotoxicity IC of the pharmaceutical composition of the present invention 50 Summary (n=3) 5.2 Virus titer determination results The results of virus titer detection are shown in Table 5. 100TCID 50 The virus infection concentration was used as an in vitro antiviral test. Table 5 Virus infection concentration of half the cells (TCID 50 ) Summary (n=8) 5.3 In vitro antiviral results of the pharmaceutical composition of the present invention The cell morphology of the cell control group was normal; the cell particles of the virus control group increased, the morphology became round, and most of them fell off; the pharmaceutical composition of the present invention can significantly inhibit the cell pathological changes caused by the virus, and as the drug concentration increases, its inhibition rate on the virus gradually increases. As shown in Table 6, the in vitro antiviral EC of the test substance pharmaceutical composition of the present invention against influenza A virus (H3N2), influenza B virus (IBV), respiratory syncytial virus (RSV), coxsackie virus (CVB3), enterovirus (EV71) and coronavirus (HCoV-229E) 50 The in vitro anti-influenza virus (PIV) and rotavirus (RV) were 71.83, 52.02, 134.60, 30.50, 5.99 and 189.80 μg / mL, respectively. Virus EC 50 The therapeutic indexes (TI) of the pharmaceutical composition of the present invention for the above viruses are 4.47, 6.17, greater than 7.43, greater than 32.79, greater than 166.94, greater than 5.27, greater than 10, and greater than 10, respectively. In the in vitro antiviral test of rhinovirus (Rhv), there was no significant difference in the survival rate of cells in the drug-added group and the virus control group, indicating that the pharmaceutical composition of the present invention has no significant inhibitory effect on rhinovirus (Rhv) in vitro. Table 6 In vitro antiviral EC 50 Results summary (n=4) 6 Conclusion and Evaluation The results showed that the pharmaceutical composition of the present invention was administered 2 hours after the host cells were infected with influenza A virus (H3N2), influenza B virus (IBV), rhinovirus (Rhv), respiratory syncytial virus (RSV), coxsackie virus (CVB3), enterovirus (EV71), coronavirus (HCoV-229E), parainfluenza virus (PIV), and rotavirus (RV) at different concentrations. After a period of culture, the virus control group showed cytopathic effects, and the normal control group had normal cell morphology. After the pharmaceutical composition of the present invention was used, the number of cells with normal cell morphology increased significantly, and cells with changed cell morphology were observed to shrink, overlap, or fall off. In addition, within the safe concentration range, the virus inhibition rate increased with the increase of drug concentration, indicating that the pharmaceutical composition of the present invention can inhibit influenza A virus (H3N2), influenza B virus (IBV), respiratory syncytial virus (RSV), coxsackie virus (CVB3), enterovirus (EV71), coronavirus (HCoV-229E), parainfluenza virus (PIV), and rotavirus (RV) in vitro. However, within the test concentration range, the pharmaceutical composition of the present invention had no significant effect on rhinovirus (Rhv) In the experiment of infecting H1HeLa cells, there was no significant difference in the cell survival rate between the group treated with the pharmaceutical composition of the present invention and the virus control group, indicating that the pharmaceutical composition of the present invention had no significant inhibitory effect on the virus in vitro. Conclusion: The pharmaceutical composition of the present invention has a strong in vitro inhibitory effect on influenza A virus (H3N2), influenza B virus (IBV), respiratory syncytial virus (RSV), coxsackie virus (CVB3), enterovirus (EV71), coronavirus (HCoV-229E), parainfluenza virus (PIV) and rotavirus (RV), and its EC50 is 71.83μg / mL, 52.02μg / mL, 134.60μg / mL, 30.50μg / mL, 5.99μg / mL, 189.80μg / mL, greater than 100μg / mL, and greater than 100μg / mL, respectively. Its therapeutic index (TI) is 4.47, 6.17, greater than 7.43, greater than 32.79, greater than 166.94, greater than 5.27, greater than 10, and greater than 10, respectively. Test Example 2 Coxsackievirus B3 is a common infectious enterovirus in the human intestine. It mainly invades perinatal infants with low immunity. After infection, it can multiply in large quantities in the gastrointestinal tract, causing gastrointestinal system disorders, mainly manifested as repeated diarrhea. If treatment is not timely, after the condition worsens, the virus can invade the blood through the gastrointestinal system, which can cause a variety of human diseases, including myocarditis, herpetic pharyngitis, aseptic meningitis, pancreatitis, Sjögren's syndrome, hand, foot and mouth disease, and even sudden neonatal death. So far, there is no specific drug treatment or vaccine defense for Coxsackievirus B3 infection. Therefore, this study uses young SD rats as research subjects, infects young SD rats by intraperitoneal injection of Coxsackievirus B3, and selects Huoxiang Zhengqi Capsules and Ribavirin Granules as positive controls to evaluate the pharmacodynamic effect of the pharmaceutical composition of the present invention against Coxsackievirus B3 infection in vivo, providing an experimental basis for its clinical research. In order to illustrate the activity of the Chinese medicine composition of the present invention in treating colds, the granules prepared in Example 1 (hereinafter referred to as the Chinese medicine composition of the present invention) were used to conduct the following efficacy test. 1 Study Objectives In this study, an in vivo infection model of Coxsackievirus B3 was established by intraperitoneal injection of young SD rats, and Huoxiang Zhengqi Capsules and Ribavirin Granules were selected as positive controls to evaluate the in vivo anti-Coxsackievirus B3 efficacy of the pharmaceutical composition of the present invention, so as to provide an experimental basis for its clinical use. 2 Experimental Materials 2.1 Test substances The pharmaceutical composition of the present invention, batch number: 211101, content: 4.5g crude drug per gram of powder, valid until: tentatively 2023.11.09. Usage and dosage: oral, 0.5g crude drug / kg. Provided by: Shijiazhuang Yiling Pharmaceutical Co., Ltd. 2.2 Positive control drug Huoxiang Zhengqi Capsules, specification: 0.3g / capsule, batch number: 210501, valid until: April 2023; manufacturer: Jiangxi Xinyuanjian Pharmaceutical Co., Ltd., provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd. Usage and dosage: oral. 4 capsules at a time, twice a day. Functions and indications: relieving exterior symptoms, eliminating dampness, regulating qi, and harmonizing the middle. Used for exogenous wind-cold, internal injury and dampness stagnation, headache, chest and diaphragm fullness, abdominal distension and pain, vomiting and diarrhea. Ribavirin granules, batch number: 200904; valid until: 2023.07; manufacturer: Sichuan Baili Pharmaceutical Co., Ltd. Indications: This product is suitable for viral pneumonia and bronchitis caused by respiratory syncytial virus, and skin herpes virus infection; Usage and dosage: For viral respiratory tract infection: 0.15g for adults once, 3 times a day, for 7 consecutive days. For skin herpes virus infection: 0.3g for adults once, 3 to 4 times a day, for 7 consecutive days. 2.3 Experimental animals 39 young SD rats (4 litters), with mothers, 7 days old, SPF grade, regardless of gender, used for the establishment of a model of young SD rats infected with Coxsackievirus B3; animal quality certificate number: 430726221100014858, purchased from Changsha Tianqin Biotechnology Co., Ltd. (production license number: SCXK (Xiang) 2019-0014); 350 young SD rats (35 litters), with mothers, 7 days old, SPF grade, regardless of gender, used for the pharmaceutical composition of the present invention to treat young SD rats infected with Coxsackievirus B3 Effect of the strange virus B3 model; Animal quality certificate number: 430727221101001215, purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. (Production License Number: SCXK (Xiang) 2019-0004). All were kept in the biosafety laboratory (ABSL-Ⅱ) of the barrier environment animal laboratory C area, experimental animal use license number: SYXK (Xiang) 2020-0015, laboratory registration number: Changweijianshibeizi (2021) No. B010, ethics review number: IACUC-2022 (2) 003-1. 2.4 Viruses Coxsackievirus B3 (CVB3), number: ATCC VR-30, provided by ATCC, USA. Cultured and amplified in the pathogenic microbiology laboratory of our center (BSL-Ⅱ, laboratory registration number: Changweijianshibeizi (2021) No. B010). 2.5 Main Reagents Rat CD4 antibody, lot number: 554838, manufacturer: BD Pharmingen; Rat CD8 antibody, lot number: 200609, manufacturer: Biolegend; Rat CD11b antibody, lot number: 17-0112-82, manufacturer: e-Bioscience; Rat CD3 antibody, lot number: 2220944, manufacturer: Thermo Fisher; Rat CD16 / CD32 antibody, lot number: 24222285, manufacturer: Thermo Fisher; Rb mAb to NCAM1 (CD56) antibody, batch number: Ab237380, manufacturer: Abcam; high glucose DMEM culture medium, specification: 500 mL / bottle, manufacturer: Gibco, batch number: 8121512; fetal bovine serum, specification: 100 mL / bottle, manufacturer: American Sciencell Company, batch number: 2300015; rat interleukin 1β (IL-1β) ELISA kit, rat interleukin 4 (IL-10) ELISA kit, rat tumor necrosis factor α (TNF-α) ELISA kit, rat gamma-interferon (IFN-γ) ELISA kit, batch number: all 202205, valid until: all 2022.11, manufacturer: Jiangsu ELISA Co., Ltd. 2.6 Main instruments BCR-MI02-72-C11-PPSU type mouse independent ventilation cage system (manufacturer: Shandong Xinhua Medical Instrument Co., Ltd.), BSC1300-Ⅱ-B2 type biological safety cabinet (manufacturer: Shandong Xinhua Medical Instrument Co., Ltd.), CJ-1F type medical purification workbench (manufacturer: Suzhou Fengshi Experimental Animal Equipment Co., Ltd.), 3111 type CO2 incubator (manufacturer: Thermo Fisher, USA), DMIL inverted microscope (manufacturer: Leica, Germany), YXQ-50A type vertical pressure sterilizer (manufacturer: Shanghai Boxun Medical Biological Instrument Co., Ltd.), TD4 type desktop low-speed centrifuge (manufacturer: Hunan Keda Industrial Development Co., Ltd.), DFC 420C pathology imaging system (manufacturer: Leica, Germany), Spectra Max i3x type multifunctional microplate reader (manufacturer: Austria Meigu Photonics Co., Ltd.), nucleic acid micro-detector (manufacturer: Thermo Fisher, USA), Beckman: A00-1-1102 flow cytometer, C6 flow cytometer (manufacturer: BD, USA). 3 Research content 3.1 Virus virulence detection 3.1.1 Cell recovery Take out the cryovial from the -80℃ refrigerator or liquid nitrogen, and quickly put it into warm water at about 37℃. Shake the cryovial constantly to make it completely thawed. Pipette the liquid in the tube into a centrifuge tube, centrifuge at 1000rpm for 5min, and discard the supernatant. Pipette an appropriate amount of complete culture medium containing 10% FBS, blow it evenly with a pipette, inoculate it into the cell bottle, add an appropriate amount of complete culture medium and place it in a 37℃, 5% CO2 incubator for culture. Note that the bottle cap should be loosened to leave a gap for gas exchange and to maintain a stable pH environment. 3.1.2 Virus amplification Take out the cryovial from the -80℃ freezer or liquid nitrogen, and quickly place it in warm water at about 37℃. Shake the cryovial constantly to completely thaw it. Add the liquid in the tube to the cultured cells, add the culture medium until it just covers the cells, and allow the virus to adsorb for 1 to 2 hours. Gently shake the culture bottle every 15 minutes to ensure uniform virus adsorption. After the virus has adsorbed for 2 hours, add an appropriate amount of virus growth solution and place it in a 33℃ to 37℃, 5% CO2 incubator for culture. 3.1.3 TCID 50 Determination TCID analysis of the virus amplified in 3.1.2 50 The specific method is as follows: (1) Cell plating: Prepare appropriate cells into 1×10 4 Cells / mL of single cell suspension were inoculated in a 96-well plate, 100 μL per well, and incubated overnight in a 37°C, 5% CO2 incubator. (2) Virus inoculation: After the cells grow to a monolayer of adherent cells, the virus stock solution is diluted 10-fold with DMEM medium to 10 -1 ~10 -6 , and 8 wells were inoculated at each dilution. The original culture medium in the 96-well plate was discarded, and the plate was washed twice with 1× PBS solution, and then 100 μL of the corresponding concentration of virus dilution was added to each well. At the same time, 8 cell wells without virus inoculation were set as negative controls. (3) Culture observation: After virus inoculation, place the 96-well cell culture plate in an incubator with corresponding culture conditions and incubate for 2 hours. Take out the culture plate every 30 minutes and gently shake it to promote virus adsorption. After 2 hours of adsorption, replace each well with 100 μL of virus maintenance solution and continue culturing. Then observe the cytopathic effect under a microscope every day, and record the number of wells with CPE. The end point is when no lesions appear at the highest dilution, and calculate TCID according to the Reed-Muench formula. 50 . Reed-Muench formula: TCID 50 = The highest logarithm of virus dilution with CPE higher than 50% + distance ratio × logarithm of dilution multiple Distance ratio value = (percentage above 50% CPE - 50%) / (percentage above 50% CPE - percentage below 50% CPE) 3.2 Establishment of the Coxsackievirus B3 Infection Model in Young SD Rats Thirty-seven young SD rats (4 litters) that passed quarantine were selected, regardless of gender, 7 days old, and randomly divided into the original solution group (6 rats), the 10 -1 Group (6), 10 -2 Group (6), 10 -3 Group (6), 10 -4 Group (4), 10 -5 Group (5), 10 -6 Each group of animals was intraperitoneally injected with 0.2 mL / animal of the corresponding concentration of CVB3. The death of animals in each group was observed after inoculation. The animals in each group were euthanized by cervical dislocation on the 7th day after virus inoculation. The heart, liver, spleen, The lung, brain, kidney and gastrointestinal tissues were fixed with 10% formaldehyde, embedded in paraffin, sectioned, and stained with HE. The pathological changes of each tissue were observed under a microscope. 3.3 Effect of the pharmaceutical composition of the present invention on the Coxsackievirus B3 model in young SD rats 3.3.1 Grouping, modeling and drug administration 350 young SD rats (35 litters) that passed the quarantine were selected, regardless of gender, 7 days old, and divided into normal control group, model control group, Huoxiang Zhengqi capsule group (0.32 g / kg), ribavirin granule group (120.7 mg / kg), low-, medium- and high-dose groups of the pharmaceutical composition of the present invention (2.0, 4.0, 8.0 g crude drug / kg), 50 animals in each group. Each group of animals was intraperitoneally injected with 0.2 mL / animal of the original solution concentration CVB3 (titer TCID 50 =10 -3.34 / 100μL), and the normal group was intraperitoneally injected with an equal amount of 0.1mmol / L phosphate buffer. Before daily administration, the pharmaceutical composition of the present invention was prepared with pure water to obtain different concentrations of the drug solution. Each group of animals was orally gavaged with the test substance of the corresponding concentration at 10mL / kg 2h after poisoning, once a day for 7 consecutive days. The normal control group and the model control group were orally administered with an equal volume of pure water. 3.3.2 Observation indicators 3.3.2.1 Tissue viral load detection Three days after administration (D4) and the day after the last administration (D8), young rats were selected from each group, 6 rats / group, and euthanized by cervical dislocation. The stomach, small intestine and large intestine tissues were dissected and placed in a homogenizer. RNA extraction solution was added at a ratio of stomach, small intestine and large intestine tissue mass (mg): RNA extraction solution (μL) = 1:2. The tissue suspension was homogenized using a high-speed homogenizer and centrifuged at 14000 rpm for 10 min at 4°C to obtain the supernatant. RNA was extracted using RNA extraction solution, and the extracted RNA was reverse transcribed into c-DNA. The fluorescence intensity of the reverse transcribed c-DNA was detected by absolute quantitative PCR, and the c-DNA fluorescence intensity was used to reflect the Coxsackievirus B3 load in the stomach, small intestine and large intestine tissues. 3.3.2.2 Histopathological examination On day 3 after administration (D4) and the day after the last administration (D8), young rats were selected from each group, 10 rats / group, euthanized by cervical dislocation, and the stomach, small intestine, and large intestine tissues were obtained by dissection. After perfusion fixation with 10% neutral formalin solution, HE staining was performed and the pathological changes of the stomach, small intestine and large intestine were observed under a light microscope. If abnormalities were found, the characteristics of the lesions were recorded and "+", "++", "+++" were recorded according to the mild, moderate and severe lesions. If no obvious abnormalities were found, NSL (no significant lesion) was recorded. 3.3.2.3 Tissue lymphocyte detection On day 3 after administration (D4) and the day after the last administration (D8), young rats were selected from each group, 6 rats / group, and blood was collected from the heart. Flow cytometry was used to detect the number of lymphocytes (CD4 + 、CD8 + ) level. 3.3.2.4 Detection of IL-1β, TNF-α, IFN-γ, and IL-10 in tissues Three days after administration (D4) and the day after the last administration (D8), young rats were selected from each group, 8 rats / group, and euthanized by cervical dislocation. The stomach, small intestine and large intestine tissues were dissected and 0.9% sodium chloride injection was added at the ratio of stomach, small intestine and large intestine tissue mass (g): 0.9% sodium chloride injection (mL) = 1:9, respectively. The mixture was ground and homogenized, and the supernatant was obtained by centrifugation at 3000 rpm for 10 min. The levels of IL-1β, TNF-α, IFN-γ and IL-10 in the stomach, small intestine and large intestine tissues were detected using rat ELISA kits. 3.3.3 Dosage design The proposed clinical dosage of the pharmaceutical composition of the present invention is: 0.5 g crude drug / kg / day. The body weight of an infant is 10 kg, and according to lgS=0.8762+0.698lgW, the body surface area is calculated to be 0.466 m 2, the body surface area of ​​young rats is calculated as 10g, and is 0.00375m 2 , according to the animal dose conversion formula D 幼 龄大鼠 =D 幼儿 ×(W 幼儿 ×S 幼龄大鼠 ) / (W 幼龄大鼠 ×S 幼儿 )=0.5g crude drug / kg×(10×0.00375) / (0.01×0.466)≈4.0g crude drug / kg, as the dosage of the dosage group in the pharmaceutical composition of the present invention (i.e., 4.0g crude drug / kg), 0.5 and 2 times of the equivalent dose are used as the dosage of the low-dose and high-dose groups of the pharmaceutical composition of the present invention, i.e., 2.0g crude drug / kg and 8.0g crude drug / kg, respectively. Huoxiang Zhengqi Capsule, clinical dosage is 4 capsules once, twice a day, specification is 0.3g / capsule. The weight of infants and young children is 10kg, according to lgS = 0.8762 + 0.698lgW, the body surface area is calculated as 0.466m 2 , the body surface area of ​​young rats is calculated as 10g, and is 0.00375m 2 , according to the animal dose conversion formula D 幼龄大鼠 =D 幼儿 ×(W 幼儿 ×S 幼龄大鼠 ) / (W 幼龄大鼠 ×S 幼儿 )=0.04g / kg×(10×0.00375) / (0.01×0.466)≈0.32g / kg. In this experiment, the rat equivalent dose was used as the administration dose of Huoxiang Zhengqi Capsule group, that is, 0.32g / kg. The clinical dosage of ribavirin granules for children is 10-15 mg / kg / day, taken in 3 divided doses for 3 days. The body weight of infants and young children is 10 kg, and the body surface area is calculated as 0.466 m according to lgS = 0.8762 + 0.698 lgW. 2 , the body surface area of ​​young rats is calculated as 10g, and is 0.00375m 2 , according to the animal dose conversion formula D 幼龄大鼠 =D 幼儿 ×(W 幼儿 ×S 幼龄大鼠 ) / (W 幼龄大鼠 ×S 幼儿 )=15mg / kg×(10×0.00375) / (0.01×0.466)=120.7mg / kg. In this experiment, the rat equivalent dose was used as the dosage of the experimental ribavirin granule group, i.e. 120.7mg / kg. The specific dosage design is shown in Table 7. Table 7 Grouping and dosage design Note: Each gram of powder contains 4.5g of crude drug. 3.4 Data processing and statistical analysis The experimental data were statistically analyzed by G test after removing outliers, and the significant figures were rounded off. The statistical software used was SPSS 22.0. The measurement data were expressed as mean ± standard deviation. Leven's test was used to test normality and homogeneity of variance. If there was no statistical significance (P>0.05), one-way analysis of variance (ANOVA) was used for statistical analysis. If ANOVA was statistically significant (P≤0.05), The LSD test (parametric method) was used for comparative analysis. If the variance was unequal (P ≤ 0.05), the Kruskal-Wallis test was used. If the Kruskal-Wallis test was statistically significant (P ≤ 0.05), the Dunnett's Test (non-parametric method) was used for comparative analysis, and the rank sum test was used for comparative analysis of frequency data. The statistical results were tested with α = 0.05 as the test limit, where P ≤ 0.05 indicated statistical significance, and P ≤ 0.01 indicated that the difference tested was very significant. 4 Experimental results 4.1 Virus virulence detection The virus titer test result is TCID 50 =10 -3.34 / 100μL. 4.2 Establishment of Coxsackievirus Infection Model in Young Rats As shown in Table 8, intraperitoneal injection of Coxsackie virus mainly causes edema in the submucosal layer of the large intestine of young rats, accompanied by a small amount of inflammatory cell infiltration. Although pathological changes of varying degrees can be seen in other stomach and small intestine tissues, the degree of change is relatively mild and has no obvious correlation with the infection dose of CVB3. No virus-related pathological changes were observed in other tissues (heart, liver, kidney, brain, spleen). Therefore, the subsequent formal test used Coxsackie virus stock solution to infect young SD rats by intraperitoneal injection, and took stomach and intestinal tissues (mainly large intestine tissues) to detect relevant indicators to reflect the infection status of the animals and the efficacy of the test substance. Table 8 Pathological results of the Coxsackievirus infection model in young SD rats 4.3 Effect of the pharmaceutical composition of the present invention on the Coxsackievirus B3 model in young SD rats 4.3.1 Effect on tissue viral load As shown in Table 9, 3 days after administration, compared with the normal control group, the viral loads in the stomach, small intestine, and large intestine tissues of the model control group rats were significantly increased (P≤0.01); compared with the model control group, the viral loads in the large intestine tissues of the medium and high dose groups of the pharmaceutical composition of the present invention were significantly reduced (P≤0.05). The viral loads in the large intestine tissues of the Huoxiang Zhengqi capsule group and the ribavirin granule group were significantly reduced (P≤0.05 or P≤0.01). As shown in Table 10, on the day after the last administration, compared with the normal control group, the viral loads in the stomach, small intestine, and large intestine tissues of rats in the model control group were significantly increased (P≤0.05 or P≤0.01), while the viral loads in the stomach, small intestine, and large intestine tissues of the other drug-administered groups only showed a decreasing trend, with no statistical difference. Table 9 Effect of the pharmaceutical composition of the present invention on the viral load of gastrointestinal tissue in the Coxsackie virus infection model of young rats - 3 days after administration (`X±S, n=6) Note: Compared with the normal control group, ++ P≤0.01; compared with the model control group, * P≤0.05, * P≤0.01. Table 10 Effect of the pharmaceutical composition of the present invention on the viral load of gastrointestinal tissue in the Coxsackie virus infection model of young rats - the day after the last administration (`X±S, n=6) Note: Compared with the normal control group, ++ P≤0.01, + P≤0.05. 4.3.2 Effects on histopathological changes As shown in Table 11, 3 days after administration, compared with the normal control group, the degree of colon, cecum and rectal tissue lesions in the animals in the model control group were significantly aggravated (P≤0.05); compared with the model control group, the degree of colon tissue lesions in the animals in the medium and high dose groups of the pharmaceutical composition of the present invention were significantly alleviated (P≤0.05). On the second day after the last administration, compared with the normal control group, the colonic lesions of the animals in the model control group were significantly aggravated (P≤0.01); compared with the model control group, the colonic lesions of the animals in the high-dose group of the pharmaceutical composition of the present invention were significantly reduced (P≤0.01). The colonic lesions of the animals in the Huoxiang Zhengqi capsule group were significantly reduced (P≤0.05). Although the gastric tissues of the animals in each group showed different degrees of gastric epithelial cavitation, the animals in the normal control group also showed gastric epithelial cavitation, so it was considered to be a background change and had no correlation with the pathological changes caused by the virus and drug intervention. Table 11 Effect of the pharmaceutical composition of the present invention on gastrointestinal pathological changes in the coxsackievirus infection model of young rats (n=10) Note: Compared with the normal control group, + P≤0.05, ++ P≤0.01; compared with the model control group, * P≤0.05, ** P≤0.01. 4.3.3 Effects on lymphocytes As shown in Table 12, 3 days after administration, compared with the normal control group, the CD8 + The proportion of lymphocytes increased significantly (P≤0.01), CD4 + / CD8 + The ratio of lymphocytes was significantly decreased (P≤0.01), CD4 + The proportion of lymphocytes showed a downward trend, but there was no statistical difference. Compared with the model control group, the CD4 + / CD8 + The lymphocyte ratio was significantly increased (P≤0.05 or P≤0.01), and the CD4 + / CD8 + The lymphocyte ratio was significantly increased (P≤0.05), and the CD8 + The proportion of lymphocytes decreased significantly (P≤0.01), CD4 + / CD8 + The lymphocyte ratio increased significantly (P≤0.01). The next day after the last administration, the CD4 + / CD8 + The lymphocyte ratio increased significantly (P≤0.05), but there was no significant difference in other groups. Table 12 Effect of the pharmaceutical composition of the present invention on lymphocytes in the coxsackievirus infection model of young rats (`X±S, n=6) Note: Compared with the normal control group, ++ P≤0.01; compared with the model control group, * P≤0.05, ** P≤0.01. 4.3.4 Effects on cytokines in tissues 4.3.4.1 Effects on TNF-α and IFN-γ As shown in Tables 13 and 14, 3 days after administration, compared with the normal control group, the TNF-α factor level in the large intestine tissue of the rats in the model control group was significantly increased (P≤0.01), and the IFN-γ factor level was significantly decreased (P≤0.05); compared with the model control group, the TNF-α factor level in the large intestine tissue of the rats in the ribavirin granules group and the low-, medium- and high-dose groups of the pharmaceutical composition of the present invention were significantly decreased (P≤0.05 or P≤0.01), the IFN-γ factor level in the large intestine tissue of the rats in the medium- and high-dose groups of the pharmaceutical composition of the present invention were significantly increased (P≤0.05), and the TNF-α factor level in the gastric tissue of the rats in the low- and high-dose groups of the pharmaceutical composition of the present invention were significantly increased (P≤0.05 or P≤0.01). On the second day after the last administration, compared with the normal control group, the level of TNF-α factor in the large intestine tissue of the rats in the model control group was significantly increased (P≤0.01), and the level of IFN-γ factor was significantly decreased (P≤0.05); compared with the model control group, the level of TNF-α factor in the large intestine tissue of the rats in the ribavirin granules group, the low-dose, medium-dose and high-dose groups of the pharmaceutical composition of the present invention was significantly decreased (P≤0.01), and the level of IFN-γ factor in the large intestine tissue of the rats in the Huoxiangzhengqi capsules group, the ribavirin granules group, the low-dose, medium-dose and high-dose groups of the pharmaceutical composition of the present invention was significantly increased. The IFN-γ factor levels in the gastric tissue of rats in the ribavirin granule group and the low-dose group of the pharmaceutical composition of the present invention were significantly reduced (P≤0.05). Table 13 Effect of the pharmaceutical composition of the present invention on TNF-α in the Coxsackie virus infection model of young rats (`X±S, n=8) Note: Compared with the normal control group, ++ P≤0.01; compared with the model control group, * P≤0.05, ** P≤0.01. Table 14 Effect of the pharmaceutical composition of the present invention on IFN-γ in the Coxsackievirus infection model of young rats (`X±S, n=8) Note: Compared with the normal control group, + P≤0.05; compared with the model control group, * P≤0.05, ** P≤0.01. 4.3.4.2 Effects on IL-10 and IL-1β in tissues As shown in Tables 15 and 16, 3 days after administration, compared with the model control group, the IL-1β factor level in the small intestinal tissue of rats in the high-dose group of the pharmaceutical composition of the present invention was significantly increased (P≤0.05). The next day after the last administration, compared with the model control group, the IL-10 and IL-1β factor levels in the gastric tissue of rats in the high-dose group of the pharmaceutical composition of the present invention were significantly increased (P≤0.05 or P≤0.01), the IL-10 and IL-1β factor levels in the small intestinal tissue of rats in the low-dose group of the pharmaceutical composition of the present invention were significantly increased (P≤0.05 or P≤0.01), and the IL-1β factor level in the small intestinal tissue of rats in the medium-dose group of the pharmaceutical composition of the present invention was significantly increased. The levels of IL-10 factor in the large intestine tissue of rats in the medium-dose group of the pharmaceutical composition of the present invention were significantly increased (P≤0.05). Table 15 Effect of the pharmaceutical composition of the present invention on IL-10 in the Coxsackie virus infection model of young rats (`X±S, n=8) Note: Compared with the model control group, * P≤0.05, ** P≤0.01. Table 16 Effect of the pharmaceutical composition of the present invention on IL-1β in the Coxsackievirus infection model of young rats (`X±S, n=8) Note: Compared with the model control group, * P≤0.05, ** P≤0.01. Coxsackievirus is a type of enterovirus and belongs to the Picornaviridae family. According to the serotype, it can be divided into Group A (serotypes 1 to 22 and 24) and Group B (serotypes 1 to 6). Among them, Coxsackievirus B3 (CVB3) has the characteristics of enteric disease and can easily proliferate in human intestinal cells, invade the bloodstream to reach the central nervous system or other target organs, causing a variety of clinical manifestations with varying degrees of severity, with latent and mild infections being the majority. The main route of transmission of Coxsackievirus is through the fecal-oral route of the digestive tract, and secretions discharged from the respiratory tract through sneezing or coughing can also be transmitted. Humans of any age can be infected Young children are more susceptible to coxsackievirus infection than adults. The coxsackievirus carrier rate in young children can be as high as 5% to 50%. The course of the disease caused is generally a latent period of 2 to 3 days, with a peak period of 3 to 5 days. It can usually heal itself in about a week, but a few cases of infection can lead to more serious consequences, and the pathogenesis after infection is still unclear. According to relevant literature reports, after infection with coxsackievirus B3, the virus will invade NK cells and CD4 + T cells, leading to an imbalance in the immune system, causing the number of NK cells and CD4 + / CD8 +The ratio of T lymphocytes decreases, and the T lymphocyte-mediated cellular immune response caused by viral invasion will further increase CD8 + The number of T cells, CD4 + / CD8 + The ratio of CD8 + The massive increase in T cells will aggregate and activate macrophage polarization, causing macrophages to secrete large amounts of tumor necrosis factor and NK cells to release interferon, thereby killing infected cells and inhibiting viral division and reproduction. This study used an in vivo model of intraperitoneal injection of CVB3 in young SD rats. The results showed that after the young rats in the model control group were infected with Coxsackie virus, viral replication caused edema and inflammatory cell infiltration in the submucosal layer of the colon, cecum, and rectum, which led to the increase of CD8 + Increased lymphocyte ratio and CD4 + / CD8 + The lymphocyte ratio decreased, which in turn caused high expression of TNF-α and low expression of IFN-γ in the large intestine tissue. The changes in immune cells and related cytokines (TNF-α, IFN-γ) in young mice after infection with CVB3 were basically consistent with the literature. After intragastric administration of different doses of the pharmaceutical composition of the present invention, 3 days after administration, the medium and high doses (4.0, 8.0 g crude drug / kg) of the pharmaceutical composition of the present invention can significantly inhibit the replication of Coxsackie virus in large intestine tissue, the medium and high doses (4.0, 8.0 g crude drug / kg) can significantly reduce the degree of colon lesions in model animals, and the low and medium doses (2.0, 4.0 g crude drug / kg) can significantly increase the CD4 + / CD8 + The ratio of lymphocytes, high dose (8.0g crude drug / kg) can significantly reduce the CD8 + Lymphocyte ratio and increase in CD4 + / CD8 + The ratio of lymphocytes, low, medium and high doses (2.0, 4.0 and 8.0 g crude drug / kg) can significantly reduce the TNF-α level in the large intestine tissue of the model animals, and the medium and high doses (4.0 and 8.0 g crude drug / kg) can significantly increase the IFN-γ level in the large intestine tissue of the model animals; the day after the last administration, the high dose (8.0 g crude drug / kg) of the pharmaceutical composition of the present invention It can significantly reduce the degree of colon lesions in model animals, and the medium dose (4.0 crude drug / kg) can significantly increase the CD4 + / CD8 +The ratio of lymphocytes, low, medium and high doses (2.0, 4.0 and 8.0 g crude drug / kg) can significantly reduce the level of TNF-α and increase the level of IFN-γ in the large intestine tissue of model animals. The above results show that the pharmaceutical composition of the present invention can significantly inhibit the replication of Coxsackie virus in large intestine tissue and increase CD4 + / CD8 + The lymphocyte ratio and IFN-γ content suggest that its mechanism of action may be to inhibit virus reproduction and maintain the balance of immune cells. Huoxiang Zhengqi Capsule, as a classic antiviral Chinese medicine with multiple ingredients, mainly achieves the therapeutic purpose by inhibiting virus reproduction and improving the body's immunity through multiple pathways. The results show that Huoxiang Zhengqi Capsule can inhibit the replication of Coxsackie virus in large intestine tissue and increase CD4 + / CD8 + The lymphocyte ratio indicates that its mechanism of action may be similar to that of the pharmaceutical composition of the present invention. The main antiviral mechanism of ribavirin is to inhibit the division and reproduction of viruses.

[0012] It can be seen that after 3 days of administration, the colon virus load of this group was greatly reduced, and due to the inhibition of viral replication, CD4 + Lymphocytes were effectively restored, and CD4 + / CD8 + The increase in lymphocyte ratio reduces the inflammatory response and alleviates the symptoms. In summary, the pharmaceutical composition of the present invention has the effects of inhibiting the replication of Coxsackievirus B3 in the large intestine tissue of young rats, regulating the balance of immune cells, and reducing the inflammatory response of local tissues. Test Example 3 Purpose of the test The effect of the pharmaceutical composition of the present invention on intestinal propulsion in normal mice was evaluated. 1 Experimental Materials 1.1 Test sample 1.1.1 Name: Pharmaceutical composition of the present invention. Sample number: GLPTN-2108. 1.1.2 Properties: This product is a brown-yellow powder mixed with white inclusion compounds; it has a slight fragrance. 1.1.3 Functions and indications: Mainly used for cold, summer-heat and dampness syndrome or influenza, damp-heat stagnation syndrome. 1.1.4 Clinical dosage and administration route: 0.5g crude drug / kg body weight, orally. 1.1.5 Content: 4.5g crude drug / g powder. 1.1.6 Source and batch number: Shijiazhuang Yiling Pharmaceutical Co., Ltd., 211101. 1.1.7 Storage conditions: sealed. 1.1.8 Validity period: tentatively set to November 9, 2023. 1.2 Positive drugs and main reagents 1.2.1 Positive drug: Huoxiang Zhengqi Capsules: Relieving exterior syndrome and resolving dampness, regulating qi and harmonizing the middle-jiao. It is used for exogenous wind-cold, internal injury by dampness, headache and dizziness, stuffiness and oppression in the chest diaphragm, abdominal distension and pain, vomiting and diarrhea. Each capsule contains 0.3 g. Orally take 4 capsules once, twice a day. Manufacturer: Jiangxi Xinyuanjian Pharmaceutical Co., Ltd. Batch number: 210408. Expiry date: until March 2023. 1.2.2 Main reagents 1.2.2.1 Sterile water for injection: Shijiazhuang No.4 Pharmaceutical Co., Ltd. Batch number: 2009053201. Expiry date: September 4, 2022. 1.2.2.2 Dextran blue 2000 (DB - 2000): Solarbio. Batch number: NO.528E053. Expiry date: October 30, 2026. 1.2.2.3 Sodium carboxymethyl cellulose (CMC - Na): Tianjin Damao Chemical Reagent Factory. Batch number: 20200525. Expiry date: May 24, 2022. 1.2.2.4 Distilled water: Guangzhou Watson's Food & Beverage Co., Ltd. Batch number: 20210417. Expiry date: October 16, 2022. 1.3 Experimental system 1.3.1 Animal species: ICR mice. 1.3.2 Animal level: SPF level. 1.3.3 Animal gender and quantity: The purchased number of animals is 60, 30 males and 30 females. 60 animals are actually used in the experiment, 30 males and 30 females. 1.3.4 Animal age: The animals are about 3 - 4 weeks old when received. 1.3.5 Animal weight: The weight range of the animals to be purchased is 18 - 22 g, the actual weight range when received is 17.0 - 22.0 g, and the weight range during feeding and drug administration is 21.5 - 30.6 g. 1.3.6 Animal source: Purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., certificate numbers: 110011210114499974, 110011210114500043, license number: SCXK(Beijing)2021 - 0006, receiving date: December 8, 2021. 1.3.7 Breeding conditions: The mice are caged and bred in the New Drug Evaluation Center of Hebei Academy of Integrative Medicine and Western Medicine, license number: SYXK(Hebei)2020 - 006. Illumination is 12 hours per day, temperature is 20 - 26 °C, and relative humidity is 40% - 70%. 1.3.8 Quarantine process: The animals are adaptively bred for 5 days, weighing once a day. During this period, the animals drink water and eat normally, are in good health, and show no signs of disease or death. 1.3.9 Feed: SPF maintenance feed for mice and rats, provided by Beijing Keao Xieli Feed Co., Ltd., feed production license number: Jingshizhi (2018)06073, batch number: 21103213, certificate number: 1112622100055093, production date: 2021.10.11, shelf life 6 months, experimental animal production license number: SCXK (Beijing) 2019-0003. 1.3.10 Drinking water: Drink clean water prepared by the ROB-B experimental animal drinking water system, fill drinking water bottles for free drinking, and conduct a full test of drinking water once a year, mainly including microbial indicators, toxicological indicators, sensory properties and general chemical indicators, which is entrusted to a qualified institution for testing; conduct a microbial limit test every 2 months, which is entrusted to the Quality Inspection Department of Shijiazhuang Yiling Pharmaceutical Co., Ltd., and the test report is kept by the animal room and archived annually. 1.3.11 Bedding: ordinary grade corn cob bedding, the bedding must be sterilized at high temperature and high pressure before use, provided by Beijing Keao Xieli Feed Co., Ltd., batch number: 21109811, production date: 2021.10.12, shelf life 6 months, experimental animal production license number: SCXK (Beijing) 2020-0010. 1.3.12 Labeling: Labeled with mouse ear tag number, Chuangbo Global (Beijing) Biotechnology Co., Ltd., item number: GERM-02. 2 Test methods 2.1 Experimental design basis 2.1.1 Adoption of standards: Determined by the "Registration Classification and Application Material Requirements for Traditional Chinese Medicine and Natural Medicine", "Good Practice for Non-clinical Drug Research", "Pharmacological Experimental Methodology (3rd Edition)" and related literature issued by the State Food and Drug Administration. 2.1.2 Instructions for experimental system selection: Gastric emptying and intestinal propulsion rate tests can be used to observe the effects of drugs on the motility of the digestive tract. Dextran blue 2000 (DB-2000) has a low gastrointestinal absorption rate and a high recovery rate. Dextran blue 2000 (DB-2000) is selected as the gastrointestinal indicator. 2.2 Dosage and grouping 60 ICR mice were randomly divided into 5 groups according to body weight, including a model group, a Huoxiangzhengqi group, a low dose group of the pharmaceutical composition of the present invention, a medium dose group of the pharmaceutical composition of the present invention, and a high dose group of the pharmaceutical composition of the present invention. According to the clinical dose of the pharmaceutical composition of the present invention, 0.5g crude drug / kg body weight is used. The medium dose of the pharmaceutical composition of the present invention for mice is set to 10 times, that is, 5.00g crude drug / kg, which is the clinical equivalent amount. The dose interval is set to 2 times, then the low and high doses of the pharmaceutical composition of the present invention for mice are 2.50 and 10.00g crude drug / kg respectively. The content of the pharmaceutical composition of the present invention is 4.5g crude drug / g powder, then the low, medium and high doses of the pharmaceutical composition of the present invention for mice are 0.56, 1.11 and 2.22g powder / kg respectively. With reference to the previous research of this laboratory and related literature, the dosage of Huoxiangzhengqi for mice is set to 0.40g / kg, as shown in Table 17. Table 17 Grouping and dosage setting of the test on the effect of the pharmaceutical composition of the present invention on intestinal propulsion in mice 2.3 Administration Administration by oral gavage is consistent with the clinical route of medication. 2.4 Preparation and storage of test samples Accurately weigh about 0.5600 g (low), 1.1100 g (medium), and 2.2200 g (high) of the pharmaceutical composition of the present invention, grind them with sterile water for injection respectively, and make the volume to 10 ml; take 1 capsule of Huoxiang Zhengqi Capsule, grind it with sterile water for injection, and make the volume to 7.5 ml. All the test drugs are prepared before use. 2.5 Administration of test articles The drug was administered with a disposable syringe at a volume of 10 ml / kg. The model group animals were given a corresponding volume of solvent for 5 consecutive days. 2.6 Steps and Observation Indicators Indicator preparation: Use 2% CMC-Na to prepare a 4% DB-2000 mixed solution. Newly received experimental animals were numbered, adaptively raised for at least 5 days, and grouped as described above. Fasting but not water control for at least 16 hours before the last administration. About 60 minutes after the last administration, each group of animals was gavaged with 0.2 ml of DB-2000 per animal. About 30 minutes later, the animals were killed by dislocation of the cervical vertebrae. The abdominal cavity was immediately opened to separate the mesentery, and the intestinal tube from the pylorus at the upper end to the ileocecal part at the lower end was cut and placed on a tray. The small intestine was gently pulled into a straight line, and the distance from the pylorus to the front end of the pigment and to the ileocecal part was measured. The ratio of the two was the small intestinal propulsion rate; the whole stomach was quickly cut, and the stomach was cut open along the greater curvature. The residual DB-2000 in the stomach was fully washed in 4 ml of deionized water, centrifuged at 3500r / min for 15 minutes, and the supernatant was taken. The absorbance was measured at 620nm with an enzyme marker. Gastric pigment residue was measured and the absorbance values ​​of each group were compared. Small intestine advancement rate (%) = (indicator advancement distance / total small intestine length) × 100% Evaluation criteria: If the pigment residue decreases and the propulsion rate increases, it means that the drug promotes gastric emptying and intestinal motility; otherwise, it inhibits gastric emptying and intestinal motility. 2.7 Notification to relevant staff Notify the animal room when purchasing animals, and notify the pathology room for treatment when animals show abnormal conditions. 2.8 Instrument system JJ2000 electronic balance, Changshu Shuangjie Testing Instrument Factory. NVT2201ZH electronic balance, Ohaus. YP-20002 electronic balance, Shanghai Yueping. Sartorius BSA2201 electronic balance, Sartorius. SYNERGY neo2 microplate reader, BioTeK. BT224S Sartorius precision analytical balance, Sartorius. Genespeed 1580R high-speed refrigerated centrifuge, GeneSpeed ​​Ltd. 2.9 Statistical methods The experimental data were analyzed and processed using SPSS20.0 statistical software. The results were expressed as mean ± standard deviation (±s). First, a normality test was performed. For data that conformed to normal distribution, one-way ANOVA was used for mean comparison. If the variances were equal, the least significant difference method (LSD) was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If it did not conform to normal distribution, a nonparametric test was used. 3 Results As shown in Table 18, compared with the model group, the small intestinal propulsion rate of the medium-dose group of the pharmaceutical composition of the present invention was significantly reduced (P<0.05), and the gastric pigment residue (absorbance) was significantly increased (P<0.05). The small intestinal propulsion rate of the high-dose group of the pharmaceutical composition of the present invention was significantly reduced (P<0.05), and the gastric pigment residue (absorbance) was significantly increased (P<0.05). The small intestinal propulsion rate of the Huoxiangzhengqi group and the low-dose group of the pharmaceutical composition of the present invention was lower than that of the model group, and the gastric pigment residue (absorbance) was higher than that of the model group, but no significant difference was found (P>0.05). Table 18 Test results of the effect of the pharmaceutical composition of the present invention on intestinal propulsion in mice Note: *P<0.05 compared with the model group. 4 Conclusion Under the experimental conditions, the pharmaceutical composition of the present invention has the effect of inhibiting gastric emptying and intestinal motility. 5 Discussions At present, dextran blue 2000 (DB-2000), Evans blue, ink, etc. are used as indicators for small intestinal propulsion in mice. Dextran blue 2000 (DB-2000) has a low absorption rate in the gastrointestinal tract and a high recovery rate, so dextran blue 2000 (DB-2000) is selected as an indicator in the gastrointestinal tract. The basic principle of this test is to inject a certain volume and concentration of Dextran Blue 2000 (DB-2000) into the stomach of normal mice, observe the pigment residue of Dextran Blue 2000 (DB-2000) in the stomach after 30 minutes, measure the absorbance at 620nm with an enzyme marker, and calculate the small intestinal propulsion rate based on the propulsion distance in the small intestine. Under the experimental conditions, the pharmaceutical composition of the present invention significantly increases gastric pigment residue (absorbance), reduces small intestinal propulsion rate, and inhibits gastric emptying and intestinal motility of normal mice. Test Example 4 Purpose of the test The effect of the pharmaceutical composition of the present invention on the diarrhea model of mice induced by oral administration of senna leaf decoction was evaluated. 1 Experimental Materials 1.1 Test sample 1.1.1 Name: Pharmaceutical composition of the present invention. Sample number: GLPTN-2108. 1.1.2 Properties: This product is a brown-yellow powder mixed with white inclusion compounds; it has a slight fragrance. 1.1.3 Functions and indications: Mainly used for cold, summer-heat and dampness syndrome or influenza, damp-heat stagnation syndrome. 1.1.4 Clinical dosage and administration route: 0.5g crude drug / kg body weight, orally. 1.1.5 Content: 4.5g crude drug / g powder. 1.1.6 Source and batch number: Shijiazhuang Yiling Pharmaceutical Co., Ltd., 211101. 1.1.7 Storage conditions: sealed. 1.1.8 Validity period: tentatively set to November 9, 2023. 1.2 Positive drugs and main reagents 1.2.1 Positive medicine: Huoxiang Zhengqi Capsule: Relieves exterior symptoms and eliminates dampness, regulates qi and harmonizes the middle. Used for exogenous wind-cold, internal injury and dampness, headache, chest tightness, abdominal distension and pain, vomiting and diarrhea. Each capsule contains 0.3g. Oral, 4 capsules at a time, twice a day. Manufacturer: Jiangxi Xinyuanjian Pharmaceutical Co., Ltd. Batch number: 210408. Valid until March 2023. 1.2.2 Main reagents 1.2.2.1 Sterile water for injection: Shijiazhuang Siyao Co., Ltd. Batch number: 2009053201. Production date: 2020.09.05. Valid until: 2022.09.04. 1.2.2.2 Distilled water: Guangzhou Watson's Food & Beverage Co., Ltd. Batch number: 20210731. Production date: 2021.07.31. Expiry date: 2023.01.30. 1.2.2.3 Senna leaves: Hebei Lin's Shengtai Pharmaceutical Co., Ltd. Batch number: 2009010841. Production date: 2020.09.19. Expiry date: 2023.09.18. 1.3 Experimental system 1.3.1 Animal strain: ICR mice. 1.3.2 Animal level: SPF level. 1.3.3 Animal gender and quantity: The number of purchased animals is 80, 40 males and 40 females. 72 animals were actually used in the experiment, 36 males and 36 females. 1.3.4 Animal age: The animals were approximately 3 - 4 weeks old when received. 1.3.5 Animal weight: The weight range of the animals to be purchased is 18 - 22 g. The actual weight range when received is 18.3 - 22.4 g. The weight range during feeding and drug administration is 21.4 - 31.0 g. 1.3.6 Animal source: Purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., certificate numbers: 110011221104102927, 110011221104103022, license number: SCXK(Beijing)2021 - 0006, receiving date: April 20, 2022. 1.3.7 Breeding conditions: The mice were caged and bred in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine, license number: SYXK(Hebei)2020 - 006. Lighting is 12 hours per day, temperature is 20 - 26 °C, and relative humidity is 40 - 70%. 1.3.8 Quarantine process: The animals were adaptively bred for 5 days, and their weights were measured once a day. During this period, the animals drank water and ate normally, had good health conditions, and showed no signs of disease or death. 1.3.9 Feed: SPF maintenance feed for mice and rats, provided by Beijing Keao Xieli Feed Co., Ltd., feed production license number: Beijing Feed License (2018)06073, batch number: 22013213, certificate number: 1112622200080198, production date: 2022.01.02, shelf life 6 months, experimental animal production license number: SCXK(Beijing)2019 - 0003. 1.3.10 Drinking water: Drink clean water prepared by the ROB-B experimental animal drinking water system, fill drinking water bottles for free drinking, and conduct a full test of drinking water once a year, mainly including microbial indicators, toxicological indicators, sensory properties and general chemical indicators, which is entrusted to a qualified institution for testing; conduct a microbial limit test every 2 months, which is entrusted to the Quality Inspection Department of Shijiazhuang Yiling Pharmaceutical Co., Ltd., and the test report is kept by the animal room and archived annually. 1.3.11 Bedding: ordinary grade corn cob bedding, the bedding must be sterilized at high temperature and high pressure before use, provided by Beijing Keao Xieli Feed Co., Ltd., batch number: 22019811, production date: 2022.01.04, shelf life 6 months, experimental animal production license number: SCXK (Beijing) 2020-0010. 1.3.12 Labeling: Animal marking pen, Japan EPS Group, item number: AM1. 2 Test methods 2.1 Experimental design basis 2.1.1 Adoption of standards: Determined by the "Registration Classification and Application Material Requirements for Traditional Chinese Medicine and Natural Medicine", "Good Practice for Non-clinical Drug Research", "Pharmacological Experimental Methodology (3rd Edition)" and related literature issued by the State Food and Drug Administration. 2.1.2 Experimental system selection instructions: Senna is a laxative that acts on the large intestine. It causes mild diarrhea, loose stools without odor, and has the advantages of low residue and high safety while achieving the best effect. Therefore, it is often used as one of the experimental methods for evaluating antidiarrheal drugs. 2.2 Dosage and grouping 72 ICR mice were randomly divided into 6 groups according to body weight, including a normal group, a model group, a Huoxiangzhengqi group, a low-dose group of the pharmaceutical composition of the present invention, a medium-dose group of the pharmaceutical composition of the present invention, and a high-dose group of the pharmaceutical composition of the present invention. According to the clinical dose of the pharmaceutical composition of the present invention, 0.5g crude drug / kg body weight, the medium dose of the pharmaceutical composition of the present invention for mice is set to 10 times, that is, 5.00g crude drug / kg, which is the clinical equivalent amount, and the dose interval is set to 2 times, then the low and high doses of the pharmaceutical composition of the present invention for mice are 2.50 and 10.00g crude drug / kg respectively. The content of the pharmaceutical composition of the present invention is 4.5g crude drug / g powder, then the low, medium and high doses of the pharmaceutical composition of the present invention for mice are 0.56, 1.11, and 2.22g powder / kg respectively. Referring to the previous research and instructions of this laboratory, the dosage of Huoxiangzhengqi for mice is set to 0.40g / kg. See Table 19. Table 19 Effect of the pharmaceutical composition of the present invention on diarrhea in mice induced by senna leaves Grouping and dosage setting 2.3 Administration The drug is administered by oral gavage, which is consistent with the intended clinical route of administration. 2.4 Preparation and storage of test samples Accurately weigh about 0.5600 g (low), 1.1100 g (medium), and 2.2200 g (high) of the pharmaceutical composition of the present invention, grind them with sterile water for injection respectively, and make the volume to 10 ml; take 2 capsules of Huoxiang Zhengqi Capsule, grind them with sterile water for injection, and make the volume to 15 ml. All the test drugs are prepared before use. 2.5 Administration of test products The drug was administered with a disposable syringe at a volume of 10 ml / kg. The animals in the normal group and the model group were given corresponding volumes of solvents, and the drug was administered continuously for 5 days. 2.6 Steps and Observation Indicators Preparation of modeling drugs: Weigh 40 g of dried senna leaves, soak them in 100°C distilled water at a solid-liquid ratio of 1:10 for 20 min, filter, repeat 3 times, combine the filtrates 3 times, concentrate to a certain volume under reduced pressure using a rotary evaporator, add cold distilled water to prepare a senna leaf decoction (containing 1 g / mL of crude drug), and set aside. The newly received animals were numbered, adaptively raised for at least 5 days, and grouped as shown above. 60 minutes after the last administration of the animals, except for the normal group, the animals in each group were gavaged with senna leaf decoction (15ml / kg) to replicate the model. The defecation volume (number of dry feces and loose feces), the presence or absence of diarrhea (with the appearance of unformed loose feces as an indicator) and the time of diarrhea in each group of animals within 6 hours were observed and recorded. After 6 hours, the diarrhea rate, diarrhea score and other indicators were calculated: Diarrhea rate = number of animals with diarrhea / total number of animals in the group × 100%. Diarrhea onset time: The time when unformed typical loose stools first appear. Diarrhea duration: the time of pure loose stools without normal stools. Diarrhea score: The standard is the amount of feces left on the filter paper (size 15.5×26.5 cm) after each time point (1 hour per time point): 0 point, no feces; 1 point, only normal feces; 2 points, the number of loose feces piles occupies less than 1 / 4 of the filter paper area; 3 points, the number of loose feces piles occupies less than 1 / 2 of the filter paper area; 4 points, the number of loose feces piles occupies more than 1 / 2 of the filter paper area. Evaluation criteria: The lower the diarrhea rate, the lower the diarrhea score, the later the diarrhea occurs, and the shorter the duration of diarrhea, the more it indicates that the drug has an antidiarrheal effect; otherwise, it does not have an antidiarrheal effect. 2.7 Notification to relevant staff Notify the animal room when purchasing animals, and notify the pathology room for treatment when animals show abnormal conditions. 2.8 Instrument system NVT2201ZH electronic balance, Ohaus. BT224S Sartorius precision analytical balance, Sartorius. NVL2101B electronic balance, Ohaus. R-300 rotary evaporator, Buchi, Switzerland. 2.9 Statistical methods The experimental data were analyzed and processed using SPSS20.0 statistical software. The results were expressed as mean ± standard deviation (±s). First, a normality test was performed. For data that conformed to normal distribution, one-way ANOVA was used for mean comparison. If the variances were equal, the least significant difference method (LSD) was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If it did not conform to normal distribution, a nonparametric test was used. 3 Results As shown in Table 20, the animals in the normal group did not have diarrhea, and the diarrhea rate of the animals in the model group was 100.00%. Compared with the normal group, the time of diarrhea was significantly shortened, the duration of diarrhea was significantly prolonged, and the diarrhea score was significantly increased (P<0.01). The diarrhea rate of the animals in the medium-dose group of the pharmaceutical composition of the present invention was 91.67%, and the time of diarrhea was significantly prolonged compared with the model group (P<0.05), the duration of diarrhea was shortened, and the diarrhea score was reduced, but no significant difference was found (P>0.05); the diarrhea rate of the animals in the high-dose group of the pharmaceutical composition of the present invention was 100.00%, and the time of diarrhea was significantly prolonged compared with the model group (P<0.01), the duration of diarrhea was shortened, and the diarrhea score was reduced, but no significant difference was found (P>0.05); the diarrhea rate of the animals in the Huoxiang Zhengqi group and the low-dose group of the pharmaceutical composition of the present invention was 100.00%, and the time of diarrhea was prolonged, the duration of diarrhea was shortened, and the diarrhea score was reduced compared with the model group, but no significant difference was found (P>0.05). Table 20 Effect of the pharmaceutical composition of the present invention on senna-induced diarrhea in mice Note: Comparison between model group and normal group ## P<0.01, *P<0.05, **P<0.01 compared with the model group. 4 Conclusion Under the experimental conditions, the pharmaceutical composition of the present invention has an antidiarrheal effect on diarrhea in mice induced by oral administration of senna leaf decoction. 5 Discussions Senna is a laxative that acts on the large intestine. The diarrhea it causes is mild, and the feces are loose and have no odor. While achieving the best effect, it also has the advantages of low residue and high safety. Therefore, it is often used as one of the experimental methods for evaluating antidiarrheal drugs. Under the experimental conditions, the pharmaceutical composition of the present invention has an antidiarrheal effect on diarrhea in mice induced by intragastric administration of senna decoction. Test Example 5 Purpose of the test The fever was induced in rats by intraperitoneal injection of lipopolysaccharide (LPS), and the antipyretic effect of the pharmaceutical composition of the present invention was observed. 1 Experimental Materials 1.1 Test sample 1.1.1 Name: Pharmaceutical composition of the present invention. Sample number: GLPTN-2108. 1.1.2 Properties: This product is a brown-yellow powder mixed with white inclusion compounds; it has a slight fragrance. 1.1.3 Functions and indications: Mainly used for cold, summer-heat and dampness syndrome or influenza, damp-heat stagnation syndrome. 1.1.4 Clinical dosage and administration route: 0.5g crude drug / kg body weight, orally. 1.1.5 Content: 4.5g crude drug / g powder. 1.1.6 Source and batch number: Shijiazhuang Yiling Pharmaceutical Co., Ltd., 211101. 1.1.7 Storage conditions: sealed. 1.1.8 Validity period: tentatively set to November 9, 2023. 1.2 Positive drugs and main reagents 1.2.1 Positive drugs: Ibuprofen granules: used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea. It is also used for fever caused by the common cold or influenza. 0.2g / bag. Take with warm water, 0.5 packs for children aged 4-8 years old at a time; 1 pack for children over 8 years old and adults at a time. If pain or fever persists, the medication can be repeated once every 4-6 hours, not more than 4 times in 24 hours. Manufacturer: CSPC Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Batch number: 363211001. Production date: 2021.10.22. Valid until: 2023.10.21. 1.2.2 Main reagents 1.2.2.1 Sterile water for injection: Shijiazhuang Siyao Co., Ltd. Batch number: 2009053201. Production date: 2020.09.05 Valid until: 2022.09.04. 1.2.2.2 LPS: Solarbio. Batch number: NO.820F036. Valid until: 2024.11.27. 1.2.2.3 Physiological saline: Shijiazhuang Siyao Co., Ltd. Batch number: 2102283202. Production date: 2021.02.28. Valid until: 2023.02.27. 1.3 Experimental system 1.3.1 Animal strain: SD rats. 1.3.2 Animal grade: SPF grade. 1.3.3 Animal sex and quantity: 100 animals were purchased, 100 of which were male. The experiment was conducted in two batches, 50 animals in each batch, from which 40 animals with moderate basal body temperature were selected for formal testing. 1.3.4 Animal age: The animals were approximately 5 weeks old when received. 1.3.5 Animal weight: The weight range of the animals to be purchased was 130 - 150 g. The actual weight range of the animals when received was 133.0 - 154.5 g. The weight range during feeding and drug administration was 194.2 - 248.1 g. 1.3.6 Animal source: Purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., certificate number: 110011220100035061, license number: SCXK(Beijing)2021 - 0011, receiving date: January 5, 2022. 1.3.7 Breeding conditions: The rats were caged and bred in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine, license number: SYXK(Hebei)2020 - 006. Lighting was 12 hours per day, temperature was 20 - 26 °C, and relative humidity was 40 - 70%. 1.3.8 Quarantine process: The animals were adaptively bred for 5 days, and their weights were measured once a day. During this period, the animals drank water and ate normally, had good health conditions, and showed no signs of disease or death. 1.3.9 Feed: SPF mouse and rat maintenance feed provided by Beijing Keao Xieli Feed Co., Ltd., feed production license number: Beijing Feed License(2018)06073, batch number: 21103213, certificate number: 1112622100055093, production date: October 11, 2021, shelf life: 6 months, experimental animal production license number: SCXK(Beijing)2019 - 0003. 1.3.10 Drinking water: The animals drank clean water prepared by the ROB - B experimental animal drinking water system. The drinking water bottles were filled for free drinking. The drinking water was fully tested once a year, mainly including microbial indicators, toxicological indicators, sensory properties, and general chemical indicators, and the testing was entrusted to a qualified institution; the microbial limit was tested once every 2 months, entrusted to the Quality Inspection Section of Shijiazhuang Yiling Pharmaceutical Co., Ltd., and the test reports were kept by the animal room and archived annually. 1.3.11 Bedding: Ordinary - grade corn cob bedding, which was used after being sterilized by high - temperature and high - pressure, provided by Beijing Keao Xieli Feed Co., Ltd., batch number: 21109811, production date: October 12, 2021, shelf life: 6 months, experimental animal production license number: SCXK(Beijing)2020 - 0010. 1.3.12 Identification: Marked with an animal marking pen, manufacturer: Japanese EPS Group, product number: AM15. 2 Test methods 2.1 Basis for test design 2.1.1 Adoption of standards: Determined by the "Registration Classification and Application Material Requirements for Traditional Chinese Medicine and Natural Medicine" and "Quality Management Standards for Non-clinical Drug Research" promulgated by the State Food and Drug Administration and related literature. 2.1.2 Instructions for experimental system selection: LPS is the active ingredient of Gram-negative bacterial endotoxin (ET). It causes fever mainly by activating inflammatory cells (mostly mononuclear macrophages) to produce pyrogens (EP). The LPS-induced fever model in rats is widely used in the evaluation of antipyretic Chinese medicines. Male animals are generally used because pharmacological doses of estrogen have anti-inflammatory and immunosuppressive effects. 2.2 Dosage and grouping Rats were randomly divided into 5 groups according to basal body temperature, namely, model group, ibuprofen group, low dose of the pharmaceutical composition of the present invention, medium dose of the pharmaceutical composition of the present invention, and high dose group of the pharmaceutical composition of the present invention. According to the clinical dose of the pharmaceutical composition of the present invention, 0.5g crude drug / kg body weight is used, and the medium dose of the pharmaceutical composition of the present invention of the rat is set to 8 times, i.e. 4.00g crude drug / kg, which is the clinical equivalent amount, and the dose interval is set to 2 times, then the low and high doses of the pharmaceutical composition of the present invention of the rat are 2.00 and 8.00g crude drug / kg respectively. The content of the pharmaceutical composition of the present invention is 4.5g crude drug / g powder, then the low, medium and high doses of the pharmaceutical composition of the present invention of the rat are 0.44, 0.89 and 1.78g powder / kg respectively. With reference to the ibuprofen instructions, the daily clinical dosage of ibuprofen is set to 200mg / person, calculated at 60kg / person, i.e. 3.33mg / kg, and the rat dosage is 8 times the clinical dosage as the equivalent dose, i.e. 26.64mg / kg. See Table 21 for details. Table 21 Experimental grouping and dosage setting of the effect of the pharmaceutical composition of the present invention on LPS-induced fever in rats 2.3 Administration The drug is administered by oral gavage, which is consistent with the intended clinical route of administration. 2.4 Preparation and storage of test samples Accurately weigh about 0.8800 g (low), 1.7800 g (medium), and 3.5600 g (high) of the pharmaceutical composition of the present invention, grind them with sterile water for injection, and make the volume to 20 ml respectively; take 1 bag of ibuprofen granules, grind them with sterile water for injection, and make the volume to 75 ml. All the test drugs are prepared before use. 2.5 Administration of test articles The drug was administered with a disposable syringe at a volume of 10 ml / kg. The model group animals were given a corresponding volume of solvent, once 30 minutes before modeling. 2.6 Steps and Observation Indicators Newly received experimental animals were fed for at least 5 days of adaptive feeding, and then the rectal temperature was measured and the gavage operation was adapted. The insertion depth of the electronic thermometer was controlled at 4 cm for at least 3 consecutive days to reduce the temperature changes caused by the operation, and the body weight was monitored at the same time. Before the formal experiment, the basal body temperature was measured once and recorded as T0. The basal body temperature was screened and grouped. After the grouping was completed, the drug was administered. 30 minutes after the drug administration, the rats were intraperitoneally injected with 20μg / kg LPS (prepared with saline) in a volume of 5ml / kg. After the model was established, the rectal temperature was measured every 1h and recorded as Tx for 5 consecutive hours, and △T was calculated, △T=Tx-T0. 2.7 Notification to relevant staff Notify the animal room when purchasing animals, and notify the pathology room for treatment when animals show abnormal conditions. 2.8 Instrument system BT224S Sartorius precision analytical balance, Sartorius. EX225D / AD Ohaus Analytical Balance, Ohaus. Sartorius BSA2201 electronic balance, Sartorius. Electronic thermometer, Omron. 2.9 Statistical methods The experimental data were analyzed and processed using SPSS20.0 statistical software. The results were expressed as mean ± standard deviation (±s). First, a normality test was performed. For data that conformed to normal distribution, one-way ANOVA was used for mean comparison. If the variances were equal, the least significant difference method (LSD) was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If it did not conform to normal distribution, a nonparametric test was used. 3 Results As can be seen from Table 22, the body temperature difference of the model group rats showed a significant upward trend 1-5 hours after intraperitoneal injection of LPS, with values ​​of 1h (0.39±0.38), 2h (0.23±0.45), 3h (0.66±0.32), 4h (0.89±0.50), and 5h (1.45±0.46). Compared with the model group, the body temperature difference of the rats in the positive drug ibuprofen group was significantly reduced 3 hours after modeling (P<0.05), and the value was 3 hours (0.28±0.48). The body temperature difference of the rats in the low-dose group of the pharmaceutical composition of the present invention was significantly reduced 5 hours after modeling (P<0.01), and the value was 5 hours (0.91±0.50). The body temperature difference of the rats in the medium-dose group of the pharmaceutical composition of the present invention was significantly reduced 5 hours after modeling (P<0.05), and the value was 5 hours (1.01±0.55). The body temperature difference of the rats in the high-dose group of the pharmaceutical composition of the present invention was significantly reduced 1 hour after modeling (P<0.05), and the value was 1 hour (0.08±0.36). Table 22 Test results of the effect of the pharmaceutical composition of the present invention on LPS-induced fever in rats Note: Compared with the model group, *P<0.05, **P<0.01. 4 Conclusion Under the experimental conditions, the pharmaceutical composition of the present invention has the effect of inhibiting fever caused by intraperitoneal injection of LPS in rats. 5 Discussions At present, the rat fever model mainly injects pyrogens into the animal body to cause fever. Pyrogens include LPS, dry yeast, 2,4-dinitrophenol, carrageenan, etc. Among them, yeast and lipopolysaccharide are both microbial fever activators, which can activate pyrogenic cells to produce and release pyrogenic cytokines. The symptoms of the LPS fever model animal during the temperature rise process are similar to the fever caused by clinical infectious inflammation, so this model is often used for antipyretic drug screening, but the dose range used in the induced fever model is large, ranging from 10-250μg / kg, among which the more commonly used doses are 10, 20, and 100μg / kg. When exploring the optimal dose of LPS-induced fever in rats, it was found that the LPS dose that caused high fever potential and long duration in rats was 20μg / kg. Because this model is self-limiting and tolerant, in the efficacy study, it is often carried out by preventing LPS attack after administration. Therefore, this experiment used LPS administration 30 minutes before intraperitoneal injection. Under the experimental conditions, the body temperature difference of the model group rats after intraperitoneal injection of LPS modeling showed a significant upward trend. The body temperature difference of the rats in the high-dose group of the pharmaceutical composition of the present invention was significantly reduced 1 hour after modeling, and the body temperature difference of the rats in the low and medium dose groups of the pharmaceutical composition of the present invention was significantly reduced 5 hours after modeling. It can be seen that the pharmaceutical composition of the present invention has the effect of inhibiting fever caused by intraperitoneal injection of LPS in rats. Test Example 6 Purpose of the test In this experiment, 0.7% acetic acid was intraperitoneally injected to induce a writhing reaction in mice, and the effect of the pharmaceutical composition of the present invention on pain was observed. 1 Experimental Materials 1.1 Test sample 1.1.1 Name: Pharmaceutical composition of the present invention. Sample number: GLPTN-2108. 1.1.2 Properties: This product is a brown-yellow powder mixed with white inclusion compounds; it has a slight fragrance. 1.1.3 Functions and indications: Mainly used for cold, summer-heat and dampness syndrome or influenza, damp-heat stagnation syndrome. 1.1.4 Clinical dosage and administration route: 0.5g crude drug / kg body weight, orally. 1.1.5 Content: 4.5g crude drug / g powder. 1.1.6 Source and batch number: Shijiazhuang Yiling Pharmaceutical Co., Ltd., 211101. 1.1.7 Storage conditions: sealed. 1.1.8 Validity period: tentatively set to November 9, 2023. 1.2 Positive drugs and main reagents 1.2.1 Positive drugs: Indomethacin capsules: The main ingredient of this product is indomethacin, which is used for: ① Arthritis, can relieve pain and swelling; ② Soft tissue injury and inflammation; ③ Antipyretic; ④ Others: used to treat migraine, dysmenorrhea, postoperative pain, post-traumatic pain, etc. Oral (1) Common dosage for adults: ① Anti-rheumatic, initial dose 25-50 mg once, 2-3 times a day, the maximum daily dose should not exceed 150 mg; ② Analgesic, first dose 25-50 mg once, followed by 25 mg, 3 times a day, until the pain is relieved, you can stop the drug; ③ Antipyretic, once 6.25-12.5 mg, not more than 3 times a day. (2) Common dosage for children: 1.5-2.5 mg / kg per day according to body weight, divided into 3-4 times. Reduce to the minimum amount after it is effective. Manufacturer: Hebei Yongfeng Pharmaceutical Co., Ltd. Batch number: 07420020143. Production date: 2020.02.29. Valid until: 2023.01. 1.2.2 Main reagents 1.2.2.1 Sterile water for injection: Shijiazhuang Siyao Co., Ltd. Batch number: 2009053201. Production date: 2020.09.05. Valid until: 2022.09.04. 1.2.2.2 Glacial acetic acid (acetic acid): Tianjin Huihang Chemical Technology Co., Ltd. Batch number: September 11, 2021. Production date: 2021.09.11. Valid until: 2024.09.10. 1.3 Experimental system 1.3.1 Animal strain: ICR mice. 1.3.2 Animal grade: SPF grade. 1.3.3 Animal sex and number: 70 animals were purchased, including 35 males and 35 females. 60 animals were actually used in the experiment, including 30 males and 30 females. 1.3.4 Animal age: Animals were approximately 3-4 weeks old when received. 1.3.5 Animal weight: The weight range of the animals to be purchased is 18-22g, the actual weight range of the animals when received is 17.8-22.6g, and the weight range after feeding and drug administration is 22.7-30.0g. 1.3.6 Animal source: purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., certificate number: 110011220101108146, 110011220101108068, license number: SCXK(Beijing)2021-0006, receipt date: February 9, 2022. 1.3.7 Feeding conditions: Mice were caged and raised in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine. License number: SYXK(Hebei)2020 - 006. Lighting was 12 hours per day, temperature was 20 - 26 °C, and relative humidity was 40 - 70%. 1.3.8 Quarantine process: Animals were adaptively raised for 5 days, and their body weights were measured once a day. During this period, the animals drank water and ate normally, had good health conditions, and showed no signs of disease or death. 1.3.9 Feed: SPF mouse and rat maintenance feed provided by Beijing Keao Xieli Feed Co., Ltd. Feed production license number: Jing Si Zheng (2018) 06073, batch number: 21113213, certificate number: 1112622200078056, production date: 2021.11.01, shelf life: 6 months, experimental animal production license number: SCXK(Beijing)2019 - 0003. 1.3.10 Drinking water: The animals drank clean water prepared by the ROB - B experimental animal drinking water system. The drinking water bottles were filled for free drinking. The drinking water was tested comprehensively once a year, mainly including microbial indicators, toxicological indicators, sensory properties, and general chemical indicators, and the testing was entrusted to a qualified institution; the microbial limit was tested once every 2 months, entrusted to the Quality Inspection Section of Shijiazhuang Yiling Pharmaceutical Co., Ltd., and the test reports were kept by the animal room and archived annually. 1.3.11 Bedding: Ordinary - grade corncob bedding. The bedding was used after being sterilized by high - temperature and high - pressure. It was provided by Beijing Keao Xieli Feed Co., Ltd., batch number: 22019811, production date: 2022.01.04, shelf life: 6 months, experimental animal production license number: SCXK(Beijing)2020 - 0010. 1.3.12 Identification: Marked with an animal labeling pen, EPS Group of Japan, product number: AM15. 2 Test methods 2.1 Basis for test design 2.1.1 Standards adopted: Determined according to the "Requirements for the Registration Classification and Application Materials of Traditional Chinese Medicines and Natural Medicines", "Good Laboratory Practice for Non - clinical Research on Drugs", "Pharmacological Experiment Methodology (3rd Edition)" promulgated by the State Food and Drug Administration and relevant literature. 2.1.2 Explanation for the selection of the experimental system: The basic principle of this test is to inject a certain volume and concentration of chemical stimulant (acetic acid) into the abdominal cavity of mice, which stimulates the visceral and parietal peritoneum, causing a deep and relatively large - area pain reaction for a long time, resulting in behavioral reactions of mice such as abdominal concavity, stretching of the trunk and hind limbs, and elevation of the buttocks, which is called the writhing reaction. The frequency of this reaction is high within 15 minutes after injection. Therefore, the number of writhing times or the number of mice with reactions within 15 minutes after injection is used as the pain quantitative index. 2.2 Dosage and grouping 60 ICR mice were randomly divided into 5 groups according to body weight, including a model group, an indomethacin group, a low dose group of the pharmaceutical composition of the present invention, a medium dose group of the pharmaceutical composition of the present invention, and a high dose group of the pharmaceutical composition of the present invention. According to the clinical dose of the pharmaceutical composition of the present invention, 0.5g crude drug / kg body weight is used. The medium dose of the pharmaceutical composition of the present invention for mice is set to 10 times, that is, 5.00g crude drug / kg, which is the clinical equivalent amount. The dose interval is set to 2 times, and the low and high doses of the pharmaceutical composition of the present invention for mice are 2.50 and 10.00g crude drug / kg, respectively. The content of the pharmaceutical composition of the present invention is 4.5g crude drug / g powder, and the low, medium and high doses of the pharmaceutical composition of the present invention for mice are 0.56, 1.11, and 2.22g powder / kg, respectively. With reference to the previous research of this laboratory and related literature, the indomethacin dosage for mice is set to 5.00mg / kg, as shown in Table 23. Table 23 Effect of the pharmaceutical composition of the present invention on acetic acid-induced writhing in mice Grouping and dosage setting 2.3 Administration The drug is administered by oral gavage, which is consistent with the intended clinical route of administration. 2.4 Preparation and storage of test samples Accurately weigh about 0.5600 g (low), 1.1100 g (medium), and 2.2200 g (high) of the pharmaceutical composition of the present invention, grind them with sterile water for injection respectively, and make the volume to 10 ml; take 1 capsule of indomethacin capsule, grind it with sterile water for injection, and make the volume to 50 ml. All the test drugs are prepared before use. 2.5 Administration of test products The drug was administered with a disposable syringe at a volume of 10 ml / kg. The model group animals were given a corresponding volume of solvent for 5 consecutive days. 2.6 Steps and Observation Indicators Newly received experimental animals were numbered, adaptively raised for 5 days, and grouped as described above. All animals were fasted for more than 12 hours before the last administration. One hour after the last administration, 10 ml / kg of 0.7% acetic acid was injected into the abdominal cavity of mice to stimulate the visceral and parietal peritoneum, causing deep, large-area, and long-term pain reactions, resulting in abdominal concavity, extension of the trunk and hind limbs, and high buttocks in mice. The latency of the writhing reaction and the number of writhing times within 15 minutes were recorded as quantitative indicators of pain. Evaluation criteria: A decrease in the number of twists and a prolonged latency period indicate that the drug inhibits the pain response; otherwise, it does not inhibit the pain response. 2.7 Notification to relevant staff Notify the animal room when purchasing animals, and notify the pathology room for treatment when animals show abnormal conditions. 2.8 Instrument system JJ2000 electronic balance, Changshu Shuangjie Testing Instrument Factory. NVT2201ZH electronic balance, Ohaus. BT224S Sartorius precision analytical balance, Sartorius. Research plus, eppendorf. 2.9 Statistical methods The experimental data were analyzed and processed using SPSS20.0 statistical software. The results were expressed as mean ± standard deviation (±s). First, a normality test was performed. For data that conformed to normal distribution, one-way ANOVA was used for mean comparison. If the variances were equal, the least significant difference method (LSD) was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If it did not conform to normal distribution, a nonparametric test was used. 3 Results As shown in Table 24, the latency of the writhing of the mice in the model group was (377.83±208.68) s, and the number of writhings within 15 minutes was (14.92±10.56) times. Compared with the model group, the latency of the writhing in the indomethacin group was significantly prolonged (P<0.01), and the number of writhings was significantly reduced (P<0.01). The latency of the writhing in the low and medium dose groups of the pharmaceutical composition of the present invention was significantly prolonged (P<0.05), and the latency of the writhing in the high dose group of the pharmaceutical composition of the present invention was significantly prolonged (P<0.01), and the number of writhings was significantly reduced (P<0.01). The number of writhings in the low and medium dose groups of the pharmaceutical composition of the present invention was reduced, but no significant difference was observed (P>0.05). Table 24 Test results of the effect of the pharmaceutical composition of the present invention on acetic acid-induced writhing in mice Note: Compared with the model group, *P<0.05, **P<0.01. 4 Conclusion Under the experimental conditions, the pharmaceutical composition of the present invention can significantly inhibit the pain response caused by acetic acid stimulating the peritoneum of mice. 5 Discussions The basic principle of this test is to inject a certain volume and concentration of acetic acid into the abdominal cavity of mice to stimulate the visceral and parietal peritoneum, causing deep, large-area, and long-term inflammatory pain, resulting in abdominal pain in mice. The behavioral reactions such as concave inward of the back, extension of the trunk and hind limbs, and raising of the buttocks are called writhing reactions. This reaction occurs frequently within 15 minutes after injection, so the writhing reaction occurring within 15 minutes after injection is used as a quantitative indicator of pain. This model is easily affected by acetic acid concentration and ambient temperature. According to literature review, when 0.7% acetic acid is injected intraperitoneally and the ambient temperature is controlled between 20-26°C, the writhing reaction is more obvious. Under the experimental conditions, the pharmaceutical composition of the present invention significantly prolongs the latency period of mouse writhing, reduces the number of writhing times, and inhibits the pain reaction caused by acetic acid stimulating the peritoneum of mice. Test Example 7 Purpose of the test A model of ear swelling induced by applying xylene, a chemical inflammatory substance, to one side of the mouse ear was adopted, and the effect of the pharmaceutical composition of the present invention on xylene-induced inflammation was observed by measuring the swelling degree, i.e., the weight difference between the two ears. 1 Experimental Materials 1.1 Test sample 1.1.1 Name: Pharmaceutical composition of the present invention. Sample number: GLPTN-2108. 1.1.2 Properties: This product is a brown-yellow powder mixed with white inclusion compounds; it has a slight fragrance. 1.1.3 Functions and indications: Mainly used for cold, summer-heat and dampness syndrome or influenza, damp-heat stagnation syndrome. 1.1.4 Clinical dosage and administration route: 0.5g crude drug / kg body weight, orally. 1.1.5 Content: 4.5g crude drug / g powder. 1.1.6 Source and batch number: Shijiazhuang Yiling Pharmaceutical Co., Ltd., 211101. 1.1.7 Storage conditions: sealed. 1.1.8 Validity period: tentatively set to November 9, 2023. 1.2 Positive drugs and main reagents 1.2.1 Positive drug: Enteric-coated aspirin tablets: The main ingredient of this product is aspirin, which can be used for chronic and acute inflammation such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Usage and dosage: Oral, 4-8g per day. Manufacturer: Bayer S.PA. Batch number: BJ55889. Production date: 2020.07.23. Valid until: 2023.07.22. 1.2.2 Main reagents 1.2.2.1 Sterile water for injection: Shijiazhuang Siyao Co., Ltd. Batch number: 2009053201. Production date: 2020.09.05. Valid until: 2022.09.04. 1.2.2.2 Xylene: Tianjin Oubok Chemical Co., Ltd. Batch number: August 3, 2021. Production date: August 3, 2021. Valid until: August 2, 2022. 1.3 Experimental System 1.3.1 Animal Strain: ICR mice. 1.3.2 Animal Grade: SPF level. 1.3.3 Animal Gender and Quantity: 70 animals were purchased, 35 males and 35 females. 60 animals were actually used in the experiment, 30 males and 30 females. 1.3.4 Animal Age: Approximately 3 - 4 weeks old when received. 1.3.5 Animal Weight: The intended purchase weight range of the animals was 18 - 22 g, the actual weight range when received was 19.1 - 23.2 g, and the weight range during feeding with the drug was 23.3 - 31.6 g. 1.3.6 Animal Source: Purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., Certificate No.: 110011220102050423, 110011220102050373, License No.: SCXK(Beijing)2021 - 0006, Receiving Date: March 2, 2022. 1.3.7 Breeding Conditions: The mice were caged and bred in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine, License No.: SYXK(Hebei)2020 - 006. The light was 12 hours per day, the temperature was 20 - 26 °C, and the relative humidity was 40 - 70%. 1.3.8 Quarantine Process: The animals were adaptively bred for 5 days, and their weights were measured once a day. During this period, the animals drank water and ate normally, had good health conditions, and showed no signs of disease or death. 1.3.9 Feed: SPF mouse and rat maintenance feed provided by Beijing Keao Xieli Feed Co., Ltd., Feed Production License No.: Beijing Feed License (2018)06073, Batch No.: 21113213, Certificate No.: 1112622200078056, Production Date: November 1, 2021, Shelf Life: 6 months, Experimental Animal Production License No.: SCXK(Beijing)2019 - 0003. 1.3.10 Drinking Water: Drinking clean water prepared by the ROB - B experimental animal drinking water system, filled into drinking water bottles for free drinking. The drinking water was tested comprehensively once a year, mainly including microbial indicators, toxicological indicators, sensory properties, and general chemical indicators, and the testing was entrusted to a qualified institution; the microbial limit was tested once every 2 months, entrusted to the Quality Inspection Section of Shijiazhuang Yiling Pharmaceutical Co., Ltd., and the test reports were kept by the animal room and archived annually. 1.3.11 Bedding: ordinary grade corn cob bedding, the bedding must be sterilized at high temperature and high pressure before use, provided by Beijing Keao Xieli Feed Co., Ltd., batch number: 22019811, production date: 2022.01.04, shelf life 6 months, experimental animal production license number: SCXK (Beijing) 2020-0010. 1.3.12 Labeling: Animal marking pen, Japan EPS Group, item number: AM15. 2 Test methods 2.1 Experimental design basis 2.1.1 Adoption of standards: Determined by the "Registration Classification and Application Material Requirements for Traditional Chinese Medicine and Natural Medicine", "Good Practice for Non-clinical Drug Research", "Pharmacological Experimental Methodology (3rd Edition)" and related literature issued by the State Food and Drug Administration. 2.1.2 Instructions for experimental system selection: Acute inflammation models often use xylene, croton oil, etc. as inflammatory agents. Xylene is a chemical reagent that can cause local capillary dilation and increased permeability when applied or injected into animals (such as ears, toes, etc.), leading to inflammatory infiltration reactions. Therefore, it is often used as one of the conventional experimental methods for evaluating anti-inflammatory drugs. 2.2 Dosage and grouping 60 ICR mice were randomly divided into 5 groups according to body weight, namely, model group, aspirin group, low dose group of the pharmaceutical composition of the present invention, medium dose group of the pharmaceutical composition of the present invention, and high dose group of the pharmaceutical composition of the present invention. According to the clinical dose of the pharmaceutical composition of the present invention, 0.5 g crude drug / kg body weight, the medium dose of the pharmaceutical composition of the present invention for mice is set to 10 times of that, that is, 5.00 g crude drug / kg, which is the clinical equivalent amount, and the dose interval is set to 2 times, then the low and high doses of the pharmaceutical composition of the present invention for mice are 2.50 and 10.00 g crude drug / kg respectively. The content of the pharmaceutical composition of the present invention is 4.5 g crude drug / g powder, then the low, medium, and high doses of the pharmaceutical composition of the present invention for mice The high doses were 0.56, 1.11, and 2.22 g of powder / kg, respectively. Referring to the instructions and literature, the aspirin dose for mice was set at 0.50 g / kg. See Table 25. Table 25 Effect of the pharmaceutical composition of the present invention on xylene-induced ear swelling in mice Grouping and dosage setting 2.3 Administration The drug is administered by oral gavage, which is consistent with the intended clinical route of administration. 2.4 Preparation and storage of test samples Accurately weigh about 0.5600 g (low), 1.1100 g (medium), and 2.2200 g (high) of the pharmaceutical composition of the present invention, grind them with sterile water for injection, and make the volume to 10 ml; take 5 enteric-coated aspirin tablets, grind them with sterile water for injection, and make the volume to 10 ml. All the test drugs are prepared before use. 2.5 Administration of test products The drug was administered with a disposable syringe at a volume of 10 ml / kg. The model group animals were given a corresponding volume of solvent for 5 consecutive days. 2.6 Steps and Observation Indicators Newly received experimental animals were numbered, adaptively raised for at least 5 days, and grouped as described above. 0.5 h after the last administration, the animals were fixed, the right ears were exposed, and xylene was dropped into the middle of the right ear of the mouse with a pipette, 15 μl on each side, and evenly applied. No treatment was done on the left ear. After 40 min, the animals were killed by cervical dislocation, and both ears were cut along the auricle baseline. The ear pieces were punched at the symmetrical parts of the two ears with a 7 mm diameter puncher, and the weights were weighed with a precision analytical balance, and the weights were recorded. The swelling degree and swelling inhibition rate were calculated. Swelling degree = weight of right ear piece - weight of left ear piece Swelling inhibition rate = (average swelling degree of model group - average swelling degree of drug administration group) / average swelling degree of model group × 100% Evaluation criteria: A decrease in swelling and an increase in swelling inhibition rate indicate that the drug has an anti-inflammatory effect; otherwise, it does not have an anti-inflammatory effect. 2.7 Notification to relevant staff Notify the animal room when purchasing animals, and notify the pathology room for treatment when animals show abnormal conditions. 2.8 Instrument system NVT2201ZH electronic balance, Ohaus. AL204 Mettler Precision Analytical Balance, Mettler. BT224S Sartorius precision analytical balance, Sartorius. Research plus, eppendorf. Hole punch, Shandong Heze Seiko Instrument Co., Ltd. 2.9 Statistical methods The experimental data were analyzed and processed using SPSS20.0 statistical software. The results were expressed as mean ± standard deviation (±s). First, a normality test was performed. For data that conformed to normal distribution, one-way ANOVA was used for mean comparison. If the variances were equal, the least significant difference method (LSD) was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If it did not conform to normal distribution, a nonparametric test was used. 3 Results As shown in Table 26, the right ears of the model group animals showed inflammatory reaction after xylene was applied, and the ear swelling was (11.14±3.60) mg. Compared with the model group, the ear swelling of the mice in the aspirin group was significantly reduced (P<0.01), and the swelling inhibition rate was 50.34%. The ear swelling of the mice in the low, medium and high dose groups of the pharmaceutical composition of the present invention was significantly reduced (P<0.01), and the swelling inhibition rates were 38.89%, 35.90% and 38.82%, respectively. Table 26 Test results of the effect of the pharmaceutical composition of the present invention on xylene-induced ear swelling in mice Note: **P<0.01 compared with the model group. 4 Conclusion Under the experimental conditions, the pharmaceutical composition of the present invention significantly inhibits xylene-induced ear swelling in mice and has an anti-xylene-induced local inflammatory effect. 5 Discussions Xylene is a chemical inflammatory agent. It is often selected as a model inflammatory agent for anti-inflammatory effects in pharmacological experiments because of its easy operation. It is used to study whether the drug has anti-inflammatory effects. Literature reports that the degree of mouse ear swelling is closely related to the xylene action time, and the optimal action time is about 40 minutes. In this experiment, the xylene action time was selected as 40 minutes. Under the experimental conditions, the swelling of the mouse ears in the low, medium and high dose groups of the pharmaceutical composition of the present invention was significantly reduced, and the swelling inhibition rates were 38.89%, 35.90% and 38.82%, respectively, indicating that the pharmaceutical composition of the present invention has a significant improvement effect on xylene-induced inflammation. Test Example 8 The clinical efficacy of the pharmaceutical composition of the present invention in treating cold wind evil attacking the surface and dampness accumulation in the middle is systematically summarized. A randomized controlled study method is adopted to enroll 90 cold patients who meet the diagnosis of this syndrome and randomly divide them into the prescription group of the pharmaceutical composition of the present invention (treated with the Chinese medicine prescription of the pharmaceutical composition of the present invention) and the blank control group (treated with general symptomatic treatment). The average course of treatment is about 5 to 7 days. The clinical cure rate / clinical cure time (the cure standard is defined as the disappearance of all major symptoms), effective rate (reduction rate of the total score of cold symptoms ≥50%), disappearance rate of single symptoms, effective rate of Chinese medicine syndrome, etc. are used as observation indicators to evaluate the clinical efficacy and safety of the pharmaceutical composition of the present invention. The results showed that the clinical cure rate of patients treated with the pharmaceutical composition of the present invention was significantly higher than that of the control group, and the median time of clinical cure was 3 days, which was significantly higher than 5 days of the control group; in terms of the effective rate of cold symptoms and the effective rate of TCM syndrome, the pharmaceutical composition prescription group of the present invention showed a good trend compared with the control group; in terms of the disappearance rate of single symptoms such as fever, aversion to wind, nasal congestion and runny nose, headache and drowsiness, nausea and vomiting, diarrhea, limb fatigue, abdominal distension, poor appetite, dry mouth and thirst, the pharmaceutical composition group of the present invention showed a good efficacy trend compared with the control group; during the study period, the prescription of the pharmaceutical composition of the present invention was safe to use, and no adverse reactions occurred. The above clinical observation and research results show that the pharmaceutical composition of the present invention has a good efficacy trend in the treatment of patients with cold wind evil attacking the surface and dampness accumulation in the middle, and has good safety. Typical case 1: Jia, female, 58 years old, visited the hospital in July 2021, complaining of fever and aversion to wind for 6 days, with symptoms of fever and aversion to wind, occasional cough, headache, drowsiness, heaviness of limbs, general fatigue, poor appetite, yellow and greasy tongue coating, and floating and slippery pulse. The original prescription of the pharmaceutical composition of the present invention was given, 1 dose per day. After taking 3 doses of the medicine, the patient was in good spirits, without fever, and the symptoms of heaviness of the head, heaviness of the limbs, general fatigue, and poor appetite were significantly improved, without nausea and vomiting, abdominal pain and diarrhea, and after taking 2 doses, the symptoms were cured. Typical case 2: Yang, female, 76 years old. In April 2021, the main reason for "fever for 2 days, aggravated for 1 day" was to see a doctor. Symptoms include poor spirit, fever and aversion to wind, occasional cough and sputum, accompanied by diarrhea, nasal congestion and runny nose, abdominal distension, poor appetite, dry mouth, pale red tongue, white and greasy fur, and slippery pulse. The original prescription of the pharmaceutical composition of the present invention was given, 1 dose per day. After taking 5 doses of the medicine, the patient was in good spirits, coughing and sputum occasionally, no fever, no nausea and vomiting, no nasal congestion and runny nose, abdominal distension and discomfort, poor appetite and poor appetite were improved, and the bowel movements were adjusted. After taking 2 doses, the patient was in good spirits, the symptoms of cough and sputum disappeared, there was no fever, no nasal congestion and runny nose, abdominal distension, poor appetite, and the bowel movements were adjusted, the tongue was pale red, the fur was white and greasy, and the pulse was slippery. The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A traditional Chinese medicine composition for treating colds, characterized in that, The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 230-340 parts of Perilla leaf, 230-340 parts of Pogostemon cablin, 230-340 parts of Mosla chinensis, 230-340 parts of Magnolia officinalis, 230-340 parts of Scutellaria baicalensis, 170-260 parts of Pinellia ternata, 285-430 parts of Lonicera hypoglauca, 230-340 parts of Forsythia suspensa, 230-340 parts of Poria cocos, 230-340 parts of Citrus reticulata Blanco, 115-170 parts of Zingiber officinale.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 230 parts of Perilla leaf, 340 parts of Pogostemon cablin, 230 parts of Mosla chinensis, 340 parts of Magnolia officinalis, 230 parts of Scutellaria baicalensis, 260 parts of Pinellia ternata, 285 parts of Lonicera hypoglauca, 340 parts of Forsythia suspensa, 230 parts of Poria cocos, 340 parts of Citrus reticulata Blanco, 115 parts of Zingiber officinale.

3. The traditional Chinese medicine composition according to claim 1, wherein The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 340 parts of Perilla leaf, 230 parts of Pogostemon cablin, 340 parts of Mosla chinensis, 230 parts of Magnolia officinalis, 340 parts of Scutellaria baicalensis, 170 parts of Pinellia ternata, 430 parts of Lonicera hypoglauca, 230 parts of Forsythia suspensa, 340 parts of Poria cocos, 230 parts of Citrus reticulata Blanco, 170 parts of Zingiber officinale.

4. The traditional Chinese medicine composition according to claim 1, wherein The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 300 parts of Perilla leaf, 300 parts of Pogostemon cablin, 300 parts of Mosla chinensis, 300 parts of Magnolia officinalis, 300 parts of Scutellaria baicalensis, 230 parts of Pinellia ternata, 380 parts of Lonicera hypoglauca, 300 parts of Forsythia suspensa, 300 parts of Poria cocos, 300 parts of Citrus reticulata Blanco, 150 parts of Zingiber officinale.

5. The traditional Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 286 parts of Perilla leaf, 286 parts of Pogostemon cablin, 286 parts of Mosla chinensis, 286 parts of Magnolia officinalis, 286 parts of Scutellaria baicalensis, 214 parts of Pinellia ternata, 357 parts of Lonicera hypoglauca, 286 parts of Forsythia suspensa, 286 parts of Poria cocos, 286 parts of Citrus reticulata Blanco, 143 parts of Zingiber officinale.

6. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 250 parts of Perilla leaf, 250 parts of Pogostemon cablin, 250 parts of Mosla chinensis, 250 parts of Magnolia officinalis, 250 parts of Scutellaria baicalensis, 200 parts of Pinellia ternata, 320 parts of Lonicera hypoglauca, 250 parts of Forsythia suspensa, 250 parts of Poria cocos, 250 parts of Citrus reticulata Blanco, 125 parts of Zingiber officinale.

7. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for treating colds, wherein the colds are influenza, common cold or gastroenteric cold.

8. The traditional Chinese medicine composition according to claim 7, characterized in that The gastroenteric cold is manifested as fever with aversion to wind, headache and dizziness, nausea and vomiting, diarrhea, nasal congestion and runny nose, heaviness of limbs, abdominal distension and pain or loss of appetite.

9. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug against H3N2, IBV, RSV, CVB3, EV71, HCoV-229E, PIV or RV virus.

10. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for inhibiting the replication of coxsackievirus B3 in large intestine tissues, regulating the balance of immune cells and reducing local tissue inflammatory reaction.

11. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for reducing the degree of colon lesions, increasing the ratio of CD4+ / CD8+ lymphocytes in blood, reducing the TNF-α level in the large intestine tissues of model animals and increasing the IFN-γ level.

12. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for inhibiting gastric emptying and intestinal motility.

13. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for treating diarrhea.

14. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of an analgesic drug.

15. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of an anti-inflammatory drug.

16. The preparation method of the traditional Chinese medicine composition according to any one of claims 1-6, characterized in that, The active ingredient of the traditional Chinese medicine composition is prepared by the following steps: (1) Weigh perilla leaf, pogostemon cablin, elsholtzia ciliata, dried tangerine peel, and ginger according to the prescription amount, extract the volatile oil by steam distillation method, collect the volatile oil for standby, and filter the aqueous solution after distillation for standby; (2) Weigh magnolia officinalis, scutellaria baicalensis, pinellia ternata, lonicera hypoglauca, forsythia suspensa, and poria cocos according to the prescription amount, extract with water, filter, and concentrate the filtrate and the aqueous solution after distillation in step (1) under reduced pressure, spray dry, and collect the spray powder for standby; The volatile oil obtained in step (1) and the spray powder obtained in step (2) together constitute the active ingredient of the traditional Chinese medicine composition.

17. A drug, which comprises the traditional Chinese medicine composition according to any one of claims 1-6 or the traditional Chinese medicine composition prepared by the preparation method according to claim 16.

18. The drug according to claim 17, characterized in that, Its dosage form is capsule, tablet, granule, injection, pill, powder, spray or oral liquid.

19. The drug according to claim 18, characterized in that, The granule is prepared by the following steps: (1) Weigh perilla leaf, pogostemon cablin, elsholtzia ciliata, dried tangerine peel, and ginger according to the prescription amount, extract the volatile oil by steam distillation method, collect the volatile oil for standby; filter the aqueous solution after distillation to obtain the volatile oil extract for standby; (2) Weigh magnolia officinalis, scutellaria baicalensis, pinellia ternata, lonicera hypoglauca, forsythia suspensa, and poria cocos according to the prescription amount, decoct with water, combine the filtrate with the volatile oil extract obtained in step (1), concentrate, filter, and dry to obtain dry extract powder for standby; (3) Select beta-cyclodextrin to include the volatile oil obtained in step (1) to obtain a volatile oil inclusion compound; (4) Granulate the dry extract powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3) with appropriate excipients, and prepare into granules according to the conventional method.

20. The drug according to claim 19, wherein, The granule is prepared by the following steps: (1) Weigh perilla leaf, pogostemon cablin, elsholtzia ciliata, dried tangerine peel, and ginger according to the prescription amount, add 8-12 times the amount of water, extract the volatile oil by steam distillation method for 6-10 hours, collect the volatile oil for standby; filter the aqueous solution after distillation to obtain the volatile oil extract for standby; (2) Weigh magnolia officinalis, scutellaria baicalensis, pinellia ternata, lonicera hypoglauca, forsythia suspensa, and poria cocos according to the prescription amount, decoct with 8-12 times the amount of water twice, each time for 1-2 hours, filter, combine the filtrate with the volatile oil extract in step (1), concentrate under reduced pressure, spray dry to obtain dry extract powder for standby; (3) Include the volatile oil obtained in step (1) with beta-cyclodextrin to obtain a volatile oil inclusion compound, dry, and pulverize for standby; (4) Granulate the dry extract powder obtained in step (2) and the dried powder of the volatile oil inclusion compound obtained in step (3) by dry granulation, and prepare into granules according to the conventional method.

21. The drug according to claim 20, characterized in that, The granule is prepared by the following steps: (1) Weigh perilla leaf, pogostemon cablin, elsholtzia ciliata, dried tangerine peel, and ginger according to the prescription amount, add 10 times the amount of water, The volatile oil was extracted by steam distillation for 8 hours, and the volatile oil was collected for later use. The aqueous solution after distillation was filtered to obtain the volatile oil extract for later use. (2) Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Lonicera hypoglauca, Forsythia suspensa, and Poria cocos were weighed according to the prescription amount, added with 10 times the amount of water, and decocted twice, each time for 1.5 hours. After filtration, the filtrate was combined with the volatile oil extract in step (1), concentrated under reduced pressure, and spray-dried to obtain dry extract powder for later use. (3) The volatile oil obtained in step (1) was included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which was dried and pulverized for later use. (4) The dry extract powder obtained in step (2) and the dried powder of the volatile oil inclusion compound obtained in step (3) were granulated by dry granulation and made into granules by a conventional method.

22. The traditional Chinese medicine composition according to claim 18, characterized in that, The tablets were prepared by the following steps: (1) Perilla frutescens, Pogostemon cablin, Elsholtzia ciliata, Citrus reticulata Blanco, and Zingiber officinale were weighed according to the prescription amount, added with 10 times the amount of water, and the volatile oil was extracted by steam distillation for 8 hours. The volatile oil was collected for later use. The aqueous solution after distillation was filtered to obtain the volatile oil extract for later use. (2) Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Lonicera hypoglauca, Forsythia suspensa, and Poria cocos were weighed according to the prescription amount, added with 10 times the amount of water, and decocted twice, each time for 1.5 hours. After filtration, the filtrate was combined with the volatile oil extract in step (1), concentrated under reduced pressure, and spray-dried to obtain dry extract powder for later use. (3) The volatile oil obtained in step (1) was included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which was dried and pulverized for later use. (4) The dry extract powder obtained in step (2) and the dried powder of the volatile oil inclusion compound obtained in step (3) were granulated by dry granulation and made into tablets by a conventional method.

23. The traditional Chinese medicine composition according to claim 18, wherein The capsules were prepared by the following steps: (1) Perilla frutescens, Pogostemon cablin, Elsholtzia ciliata, Citrus reticulata Blanco, and Zingiber officinale were weighed according to the prescription amount, added with 10 times the amount of water, and the volatile oil was extracted by steam distillation for 8 hours. The volatile oil was collected for later use. The aqueous solution after distillation was filtered to obtain the volatile oil extract for later use. (2) Magnolia officinalis, Scutellaria baicalensis, Pinellia ternata, Lonicera hypoglauca, Forsythia suspensa, and Poria cocos were weighed according to the prescription amount, added with 10 times the amount of water, and decocted twice, each time for 1.5 hours. After filtration, the filtrate was combined with the volatile oil extract in step (1), concentrated under reduced pressure, and spray-dried to obtain dry extract powder for later use. (3) The volatile oil obtained in step (1) was included with beta-cyclodextrin to obtain a volatile oil inclusion compound, which was dried and pulverized for later use. (4) The dry extract powder obtained in step (2) and the dried powder of the volatile oil inclusion compound obtained in step (3) were granulated by dry granulation and made into capsules by a conventional method.

24. A method for treating a disease, which includes administering the traditional Chinese medicine composition according to any one of claims 1-6, or administering the traditional Chinese medicine composition prepared by the preparation method according to claim 16, or administering the drug according to any one of claims 17-23.

25. The treatment method according to claim 24, characterized in that, The treatment includes at least one of the following: treating colds, inhibiting gastric emptying and intestinal motility, treating diarrhea, relieving pain, and / or anti-inflammatory.

26. The treatment method according to claim 25, characterized in that, The colds include influenza, common cold, or gastrointestinal cold.

27. The treatment method according to claim 26, wherein, The gastrointestinal cold is manifested as fever and aversion to wind, headache and dizziness, nausea and vomiting, diarrhea, nasal congestion and runny nose, limb heaviness, abdominal distension and pain, or loss of appetite.

28. The treatment method according to claim 25, characterized in that, The treatment for colds includes: anti-H3N2, IBV, RSV, CVB3, EV71, HCoV-229E, PIV or RV viruses.

29. The treatment method according to claim 28, characterized in that, The treatment for colds includes at least one of the following: Inhibiting the replication of coxsackievirus B3 in large intestine tissues, regulating the balance of immune cells, and reducing local tissue inflammatory responses; Reducing the degree of colon lesions, increasing the ratio of CD4+ / CD8+ lymphocytes in the blood, decreasing the TNF-α level in the large intestine tissues of model animals, and increasing the IFN-γ level.